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RESUMO 
Gliomas são tumores cerebrais que têm origem em dois tipos de células: os astrócitos e os 
ologodendrócitos, os quais formam uma estrutura de suporte para os neurónios. Os gliomas são 
responsáveis por cerca de 80 % dos casos malignos de tumor cerebral. 
A classificação de gliomas fundou-se durante muito tempo em parâmetros histológicos, tais como o 
tipo histológico ou o estádio do tumor, uma medida do seu grau de malignidade, baseada na 
aparência e comportamento das células. A realização de estudos de larga escala fazendo uso das 
novas tecnologias ómicas, tem permitido melhorar os sistemas de classificação clássicos, através da 
identificação de assinaturas moleculares subjacentes aos diferentes subtipos tumorais. No caso de 
gliomas, uma publicação recente fez a descrição de um sistema de classificação robusto, baseado 
num painel de 1300 marcadores de metilação de DNA, aplicável a tumores dos estádios de 2 a 4, em 
que são definidos seis subtipos (LGm1 a LGm6) que formam grupos prognóstico bastante 
homogéneos (Ceccarelli et al., 2016).  
O splicing é um mecanismo de processamento pós-transcricional através do qual certos segmentos 
de uma molécula de pre-RNA mensageiro (pre-mRNA): os intrões, são eliminados, resultando num 
mRNA maduro constituído por segmentos chamados exões que codifica para uma proteína (ou 
produto génico). É um processo químico levado a cabo por um complexo macromolecular modular, 
que se designa por spliceossoma. O splicing alternativo consiste na produção de mais do que um 
tipo de mRNA maduro a partir do mesmo gene através da retenção ou eliminação seletiva de um 
exão/intrão, dito alternativo ou regulado. Este processo contribui para a geração de diversidade 
funcional de produtos génicos e é regulado de forma específica em cada tecido e estádio de 
desenvolvimento, sendo que alterações aos seus padrões normais estão descritos como podendo 
promover ou apoiar o processo de tumorigénese.  
A quantificação de splicing alternativo pode ser feita usando uma medida que se designa por index 
da percentagem de splicing ou PSI, e que corresponde à proporção de transcritos que incluem um 
exão regulado em relação ao total de transcritos de um gene.  
O presente projeto de tese visa analisar a contribuição da regulação de splicing alternativo para a 
definição da classificação dos gliomas de estádios 2 a 4, tendo como objeto de estudo o conjunto de 
dados de uma coorte de 674 casos de glioma depositado no portal TCGA (The Cancer Genome Atlas).  
Por forma a avaliar a existência de uma assinatura molecular própria ou associada aos subtipos de 
glioma estabelecidos, utilizou-se análise multivariada dos dados de quantificação de splicing 
alternativo, mas também de expressão génica. Utilizando análise de componentes principais (PCA), o 
splicing alternativo mostrou capturar diversidade biológica de forma muito semelhante à expressão 
génica. A componente principal associada aos dois níveis de dados transcriptómicos de maior 
relevância representou um gradiente de malignidade tumoral. O splicing alternativo demonstrou ser 
informativo relativamente à distinção dos subtipos LGm2, LGm3 e LGm4/5, enquanto os subtipos 
LGm1 e LGm6 revelaram uma grande heterogeneidade.  
Análise de expressão génica e splicing alternativo diferencial ao longo dos subtipos LGm permitiu 
identificar um grupo de 5970 genes e 1762 eventos de splicing associados à definição desses 
subtipos. De forma importante, 183 genes e 105 eventos de splicing com regulação diferencial 
afetam genes cujas mutações têm implicação causal em cancro demonstrada. Por fim, 41 fatores de 
splicing apresentaram de igual modo expressão génica diferencial entre subtipos, com os genes 
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IGF2BP2 e IGF2BP3 apresentando os resultados mais significativos, nomeadamente uma expressão 
elevada em LGm1,4,5 e 6, os subtipos associado a um pior prognóstico. 
Análise de enriquecimento funcional realizada com a informação de regulação diferencial da 
expressão génica e splicing alternativo entre subtipos LGm revelou funções bilógicas distintas por 
cada processo. Enquanto os genes com alterações de expressão entre grupos de metilação de DNA 
se relacionaram com funções como resposta imune, proliferação, sobrevivência e adesão celulares, 
genes tendo o seu splicing alternativo alterado involveram sobretudo o processamento de RNA, 
síntese proteica e também apoptose. 
O valor do splicing alternativo e da expressão génica para o prognóstico em gliomas foi avaliado 
usado modelos de regressão de Cox para a sobrevida do paciente em função de diferentes fatores 
de risco. Um teste inicial sobre a capacidade da componente principal associada à malignidade para 
explicar a evolução do tempo de sobrevida do doente confirmou a superioridade desta dimensão 
dos dados de transcriptómica relativamente à variável estádio do tumor no que diz respeito a essa 
previsão. Subsequente análise de eventos de splicing e genes individuais como preditores de 
prognóstico resultou na descoberta de tantos quantos 11794 genes e 6657 eventos de splicing. 
Porém, apenas um gene e dois eventos de splicing alternativo foram capazes de melhorar a 
estimativa da evolução do doente relativamente a um modelo já contendo subtipos LGm, estádio do 
tumor e idade do doente, três covariáveis relevantes descritas na literatura. Os dois eventos em 
questão apresentaram distribuições de PSIs com variãncia muito baixa, pelo que constituiriam 
marcadores de prognóstico de pouca qualidade, além de não parecerem ter um interesse intrínseco 
já que não representam a possibilidade de geração de uma transição de uma isoforma dominante 
para outra. Finalmente, marcadores especificamente associados aos grupos LGm foram identificados 
a partir da interseção do conjunto que apresentou valor prognóstico independente do estádio do 
tumor e da idade do doente com o conjunto com regulação diferencial entre os seis subtipos. Desta 
análise resultou um total de 337 eventos de splicing alternativo, 50 dos quais acrescentando 
informação prognóstica relativamente aos dados de expressão génica, e também 20 genes de 
fatores de splicing. De entre estes últimos, seis codificavam para proteínas que se ligam ao RNA 
(RBPs) com motivos de ligação conhecidos, pelo que o seu potencial papel regulatório foi 
investigado. 
Uma metodologia para a descoberta de mecanismos de regulação de splicing alternativo em trans 
foi implementada. Concretamente, um algoritmo para a geração de mapas de regulação de splicing 
específicos de cada RBP foi usado, tendo como objetivo determinar as regiões regulatórias para 
fomento ou silenciamento do splicing de exões alternativos. A identificação da posição relativa dos 
alvos de regulação de cada RBP baseou-se na deteção dos eventos de splicing cujas percentagens de 
inclusão do exão alternativo se correlacionavam com a abundância da RBP e que efetivamente 
continham motivos de ligação para essa RBP nas regiões vizinhas do exão regulado. Este método foi 
validado para o fator de splicing bem estudado PTBP1, utilizando tanto um conjunto de dados 
provindo de tecidos saudáveis como com o da cohorte de glioma estudada. No entanto, a aplicação 
do mesmo procedimento a quatro dos seis fatores de splicing potencialmente associados com as 
alterações de splicing entre subtipos de glioma resultou em mapas de splicing de RNA inconsistentes 
entre os dois conjuntos de dados. Medidas para a melhoria desta metodologia foram identificadas e 
poderão ser aplicadas futuramente por forma a poder concluir sobre a relevância destas proteínas 
em glioma. 
Este estudo permitiu identificar um número de eventos de splicing alternativo e genes expressos, 
nomeadamente, genes de fatores de splicing, que apresentam comportamento diferencial em 
termos de malignidade e subtipo epigenático de glioma e que poderão ter valor diagnóstico e 
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terapêutico interessante. Adicionalmente, um novo método computacional para descoberta de 
mecanismos de regulação de splicing alternativo foi implementado, tendo permitido propor um 
mecanismo de ação para o fator de splicing relevante em glioma KHDRBS2.  
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ABSTRACT 
Gliomas are brain primary tumours that originate from two kinds of glial cells: astrocytes and 
oligodendrocytes, which make up a supportive structure for neurons. 
Classification of gliomas has for long relied on histological parameters, like cell type composition and 
grade, a measurement of the degree of malignancy of a tumour based on cell appearance and 
behaviour. Large scale studies employing the new omics technologies have allowed to improve 
classic classification systems, through the identification of molecular signatures behind each tumour 
subtype. In the case of gliomas, a recent publication described a robust classification system based 
on DNA-methylation profiling, applicable to tumours from grades 2 to 4 and defining six subtypes 
(LGm1 to LGm6) forming quite homogeneous prognostic groups (Ceccarelli et al., 2016). 
Alternative splicing is a post-transcriptional mechanism of regulation of gene expression that 
contributes to generate functional diversity of gene products through the selective elimination of 
certain segments of pre-messenger RNA (pre-mRNA) molecules. Alternative splicing is regulated in a 
tissue and developmental specific way and alterations to its normal patterns have been extensively 
reported to promote or help sustaining tumorigenesis. 
The work presented here aimed at determining the contribution of alternative splicing to glioma 
subtype definition, having as a focus a cohort of 674 cases of glioma grades 2 to 4, coming from the 
Cancer Genome Atlas (TCGA) data portal.  
Differential gene expression and differential splicing analyses across LGm subtypes allowed to 
identify a group of 5970 genes and 1762 events of alternative splicing whose regulation is associated 
with subtype definition. Importantly, among these differentially regulated markers, there were 41 
splicing factor genes and 46 splicing factor gene-associated events of splicing. 
In order to enquire about the existence of particular molecular signatures in glioma, multivariate 
exploratory data analysis was performed on alternative splicing and also gene expression data. 
Alternative splicing showed to capture sample diversity in a way that was very similar to gene 
expression. The most revealing principal component associated with both transcriptomic data levels 
presented a gradient of tumour malignancy. As for the ability of alternative splicing to distinguish 
subtypes, it could partially separate LGm2, LGm3 and LGm4/5 groups, while LGm1 and LGm6 
revealed a high heterogeneity.  
The value of alternative splicing and gene expression in glioma prognosis was evaluated using Cox 
regression models for patient’s overall survival outcome as a function of different predictors. An 
initial test on the ability of the malignancy associated principle component to explain patient 
outcome strikingly confirmed the superiority of this dimension of transcriptomic data to make this 
prediction in relation to tumour grade. In turn, analysis of individual alternative splicing events and 
expressed genes as prognosis predictors resulted in as many as 11794 genes and 6657 events of 
splicing. However, only one gene and two alternative splicing events were able to improve patient 
survival outcome estimation relative to a model that already accounted for LGm subtype, tumour 
grade and patient age, three relevant covariates described in the literature. Finally, in terms of 
prognostic markers specifically associated with LGm groups, a total of 337 splicing events were 
found, 50 of which adding information in relation to gene expression, and also 20 splicing factor 
genes. From these latter, six encoded RNA-binding proteins (RBPs) with known RNA-binding motifs 
and their potential regulatory role was investigated. 
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A methodology for the discovery of mechanisms of alternative splicing regulation in trans was 
implemented. Specifically, an algorithm to generate maps of splicing regulation specific of each RBP 
was used, aimed at determining regulatory regions for their enhancing or silencing role in splicing of 
alternative exons. This method was validated for the known splicing factor PTBP1, both using an 
RNA-seq dataset from healthy tissues and the studied glioma one. However, application of the same 
procedure to four of the six splicing factors potentially associated with alternative splicing changes 
across glioma subtypes resulted in RNA splicing maps that were inconsistent between the two 
datasets. Improvements to the methodology used were identified and may be applied in the future 
so that stronger conclusions about the relevance of these proteins in glioma can be taken. 
This study allowed to outline a number of alternative splicing events and expressed genes, namely 
splicing factor genes, that behave differently according to glioma malignancy and epigenetic groups 
and that may be of interesting diagnostic and therapeutic value. Also, a novel computational method 
for discovery of mechanisms of regulation of alternative splicing was implemented and allowed to 
proposal a mechanism of action for the glioma-relevant splicing factor KHDRBS2. 
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1. INTRODUCTION 
 
In this thesis, the alternative splicing patterns of glioma, the central-nervous system (CNS) glial-cell 
derived tumour type, will be studied. The introductory text that follows will cover (1) overall 
background related to this type of tumour, and its classification system, (2) the theory behind 
alternative splicing mRNA processing, as well as the methodological approaches taken to be able to 
study splicing transcriptional output and, finally, (3) an overview over what is known in terms of the 
role of alternative splicing in gliomagenesis.  
1.1 GLIOMA 
1.1.1 The most pervasive CNS primary tumour 
Glioma, without being the most frequent primary tumour affecting the brain, does account for about 
80 % of the malignant cases. Indeed, data from the 2008-2012 report from the Central Brain Tumour 
Registry of the United States estimate that, from the 32.8 % of malignant cases, 15.1 % are 
glioblastomas, the most aggressive glioma type, and 11.3 % correspond to other malignant gliomas 
(Figure 1.1) (Ostrom et al., 2014).  The remaining 1.1 % of gliomas are benign, i.e. have a slow pace, 
localized growth, which makes them not life threatening once diagnosed.  
 
Figure 1.1 – Distribution of Primary Brain and CNS Tumours by behaviour  (N = 356,858), CBTRUS 2008-2012 Statistical 
Report (Ostrom et al., 2014) . 
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1.1.2 Cells of origin 
Cells from the glia make up a supportive structure for neurons in the brain. They can be of four 
essential types: astrocytes, oligodendrocytes, microglia, and ependymal cells (Snell, 2010). 
Astrocytes are at least as numerous as neurons and responsible for controlling ion levels and the pH 
at the neurological synapse, for providing nutrients to neurons (e.g. glucose and metabolic 
intermediates), to clear out neurotransmitters or other neuron-secreted compounds from the 
extracellular space, and for helping define the blood-brain barrier by means of interaction with 
blood-vessel endothelial cells (Nedergaard, Ransom, & Goldman, 2016). Oligodendrocytes are cells 
that electrically insulate neuronal processes by wrapping them around myelin sheets. These two 
latter cell types are also the ones that lead to glioma formation. In fact, gliomas appear as cell 
masses of astrocyte-like, oligodendrocyte-like or a mixture of astrocyte- and oligodendrocyte-like 
cells. Interestingly, these two-cell types originate from the same population of cells that also give 
rise to neurons, which may be called the neuroglial progenitors, and are responsible for neural/glial 
tissue regeneration (Modrek, Bayin, & Placantonakis, 2014).  
As for the other glial cell types, which do not share a common developmental origin with the 
neuroglial cells, microglia are monocyte-like cells that can act like macrophages and have a neuro-
protective role and ependymal cells are multi-ciliated cells that line up the brain ventricles and 
propel the cerebrospinal fluid. 
1.1.3 Classification of Glioma 
The definition of glioma subtypes is still an ongoing process, which has gained much improvement in 
the last years, with the contribution of studies that integrate histological and high-throughput 
molecular data to then relate it with patient survival data. Glioblastoma has been subjected to more 
thorough research before lower-grade gliomas (LGG) did and the description that follows reflects 
this chronological order in the evolution of glioma classifiers.  
1.1.3.1 The Cancer Genome Atlas as a privileged source for cancer research 
Cancer, being a complex disease, will arise as a result of genetic background and environmental 
exposures that are particular to the individual carrying it. As such, research on its aetiology will be 
complicated by the presence of “passenger” mutations or other cellular alterations carried by the 
individual, but that do not contribute to the development of the disease. This creates the need to 
carry out cancer studies in as large cohorts as possible and preferably to get access to clinical 
parameters that will allow not only to relate subtypes of the disease with particular cancer patient 
strata but also to establish a direct link between a molecular signature and the progression of the 
disease within an individual clinical case.   
The Cancer Genome Atlas (TCGA) is a project created in 2005, as a collaboration between the US 
National Cancer Institute (NCI) and the US National Human Genome Research Institute (NHGRI), with 
the aim to create a very large source of molecular, histological and clinical data relative to more than 
11000 cancer cases and 35 tumour types, all put together and made available for public use (“TCGA 
Home - TCGA - National Cancer Institute - Confluence Wiki,” 2016). The project had a very important 
impact on cancer research done worldwide, due to a very effective spread of the information. To 
start with, the existence of a network of researchers more directly implicated in the development of 
the project guaranteed the publication of the main findings gathered around multi-platform data 
analysis from each cancer cohort. Then, a free-access data portal was made available to the scientific 
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community (“The Cancer Genome Atlas - Data Portal,” 2016), with releases occurring even before 
publication. Access to this large amount of data, collected and analysed according to high quality 
standards, can be done at different levels or tiers, with tier 3 corresponding to access to clinical and 
processed data files, while tier 1, controlled access, includes access to all raw sequencing data (e.g. 
exome-sequencing, RNA-sequencing, bisulfite sequencing) and also additional information on 
patients’ genetic variants. Finally, cancer genomics online portals like cBioPortal (“cBioPortal for 
Cancer Genomics,” 2016) or COSMIC (“COSMIC: Catalogue of Somatic Mutations in Cancer - Home 
Page,” 2016) have been created or largely expanded through incorporation of TCGA data into their 
databases, which constitutes a very useful tool to be used by basic and applied researchers or by 
geneticists.   
1.1.3.2 Glioma classification systems 
Glioblastoma multiforme (GBM), a WHO grade IV tumour (Louis et al., 2007), is the most aggressive 
glioma type known, characterized by a high capacity to invade the surrounding tissue, high 
proliferation rates, abundant vascularization and a large amount of necrotic cells. It has also been 
characterized by the presence of numerous copy-number variants (CNV), mostly amplification of 
EGFR, PDGFRA, CDK4, MDM2 and MDM4, amplification and or mutation of class II 
phosphatidylinositol 3-kinase (PI3K) genes, deletion or mutation of PTEN, NF1, RB1, CDKN2A and 
CDKN2B genes, and deletion of chromosome arm 10q (Brennan et al., 2013; Network, 2008). The 
alterations described affect three main signalling pathways relevant for cancer progression: the 
growth factor receptor tyrosine kinase (RTK) pathway, the p53 apoptotic pathway and the 
retinoblastoma (Rb) cell cycle progression pathway. In 2010, another study created a GBM subtype 
classifier, which consisted of four groups of tumours: Proneural, Neural, Classical and Mesenchymal, 
carrying mutually exclusive combinations of the previously mentioned RTK-related genomic 
abnormalities and, importantly, alterations in gene expression coherent with those mutations 
(Verhaak et al., 2010). More specifically, the Classical subtype was associated with EGFR 
overexpression, Mesenchymal subtype with NF1 downregulation and the Proneural subtype with 
both PDGFRA overexpression and IDH1 downregulation. The four groups described were found to 
correspond to similar patient prognosis. However, an interesting observation in terms of the 
usefulness of this GBM classifier for clinical management of patients was made: patients carrying a 
Classical subtype GBM were much more responsive to aggressive chemo- and radiotherapy, having 
improved survival times when treated, than patients carrying the Proneural subtype, which were 
almost unresponsive to treatment. 
A new picture about the ability to define strata of patients with clearly different prognosis emerged 
from studies where DNA methylation profiling was carried out. Noushmehr and collaborators found 
that GBM and lower grade glioma (LGG) patients carrying a mutation in the IDH1 gene had a high 
level of DNA methylation of their gene promoters in relation to patients carrying unaffected, wild-
type copies of IDH1 (Noushmehr et al., 2010). They termed this phenotype of high or low CpG island 
methylation as glioma-CpG island methylator phenotype, or G-CIMP, and found it to be more 
prevalent among LGG cases, in association with better prognosis. 
Yet another two subtypes of GBM tumour involving epigenetic alterations have been identified 
(Sturm et al., 2012), which are found only in paediatric cases, each one dealing with a mutation 
affecting amino acids K27 or G34 of the histone H3.3.  
As for LGG (grades II and III), genomic sequencing and CNV analysis has also allowed to get a good 
overall picture of their associated genetic lesions. One of the works that better made this description 
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is the work of Suzuki et al. (Suzuki et al., 2015), where three main types of grade II and III gliomas are 
defined and which brought as main findings, on the one hand, the presence of at least one CNV in 
roughly all tumour samples, the most frequent of which being a co-deletion of chromosome arms 1p 
and 19q, and, on the other hand, frequent mutations in the following genes: IDH1, TERT promoter, 
TP53, ATRX, CIC and FUBP1, with particular note going to IDH1 gene, which was estimated to be 
mutated in 75 % of grade II and III gliomas. The three types of LGG consisted then of: type I, carrying 
mutated IDH, a 1p/19q codeletion and TERT promoter mutation, with or without CIC and FUBP1 
mutations; type II LGG were also IDH-mutant, TP53-mutant and frequently carried ATRX mutations, 
resulting in a lower overall survival of patients in relation to type I tumours; type III LGG patients, 
which were the group found to have worst prognosis, closer to the one of GBM patients (29.1 % rate 
of 5-year survival), carried a normal copy of IDH1 and also mutations similar to the ones found in 
GBM, affecting e.g. EGFR, PDGFRA, PTEN, RB1 genes.  
Figure 1.2 – Defining features of pan-Glioma classification proposed in (Ceccarelli et al., 2016) and its relation with other 
established glioma classifications and clinical parameters.  Image adapted from (Ceccarelli et al., 2016). 
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Because there was a superposition of genomic lesions among GBM and LGG, it became clear the 
need to create a pan-glioma classifier. This was accomplished already this year, by Ceccarelli and 
collaborators (Ceccarelli et al., 2016), who, based on DNA-methylation profiling, were able to, with 
one single molecular analysis platform (bisulfide sequencing), build a pan-glioma classifier that is 
able to identify six main groups: LGm1 to LGm6 termed LGm DNA methylation clusters (Figure 1.2). 
Moreover, the authors show that this epigenetic molecular signature has prognostic value. Indeed, 
the authors show, using the same cohort of patients, that the power to predict patient outcome 
using this new DNA methylation classification, together with tumour grade and age of the patient, is 
superior to the one of any other classifier previously described, alone or when combined with the 
same two clinical variables. 
A new classification of tumours affecting the CNS has been recently published by the World Health 
Organization (WHO), which makes use for the first time of molecular information associated to 
specimens, together with histological information (see Table S1 for a summary of the novel glioma 
classification) (Louis et al., 2016).  
 
1.2 ALTERNATIVE SPLICING 
Splicing is one of the mechanisms of messenger RNA (mRNA) processing whereby pieces of the 
transcribed molecule are selectively eliminated. As a result, splicing plays fundamental roles in 
dictating the stability of the mRNA species produced and, most of all, in deciding which protein will 
be generated from the mature mRNA. In fact, splicing is known to lead, within the same organism 
and even in the same cell, to the production of distinct transcripts and corresponding protein 
products, in a process that is regulated in order to meet the cell’s needs in terms of protein 
composition. This concurrent generation of diverse transcript species from one gene through splicing 
is called alternative splicing (AS), which will be described in the following sections.   
1.2.1 Alternative Splicing and Its Regulation 
Splicing is a chemical reaction by which segments of the pre-mRNA that are not to be incorporated 
in the mature RNA, called introns, are extracted, while the remaining mRNA segments, called exons, 
are joined to remake a continuous RNA strand (Figure 1.3A). Each of these reactions can be called an 
event of splicing. It occurs through two trans-esterification reactions, the first one involving the 3’ 
hydroxyl group of an adenosine residue in the intron, called the branch point, and the phosphate of 
the guanosine residue located at the starting position of the intron: the 5’ splice site. This reaction 
originates the formation of a loop-like structure (lariat). A second similar reaction follows that 
consists on the interaction of the 3’ hydroxyl group of the exon that was displaced with the 
phosphate group of the 3’splice site, a reaction that results in the junction of the two exons and the 
release of the lariat segment, which will be targeted for degradation.   
Splicing is carried out by a modular protein complex, called the spliceosome, whose composition 
changes dynamically and, most of all, whose catalytic protein subunits responsible for carrying out 
the splicing reaction only assemble after the exon boundaries, the 5’ splice site and 3’ splice site, 
have been located. The recognition of the 5’ and 3’ splice sites is done by the U1 and U2 small 
nuclear ribonucleoproteins (snRNPs), respectively, which bind those sites by RNA base-pairing. 
Because the sequences of the splice sites are not always the same (Figure 1.3B), these are bound as 
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efficiently as their sequence affinity for the U1/U2 snRNPs, a condition that turns them into strong 
or weak splice sites.  
Alternative splicing occurs in all eukaryotic cells, and is known to be abundant in organisms like 
plants and in human, whose 90 % of genes enable the creation of more than one transcript and 
protein isoform each (Pan, Shai, Lee, Frey, & Blencowe, 2008; Yang et al., 2016).  
This process occurs in a tissue and developmental stage specifically regulated way and relies on the 
frequency with which the U1/U2 snRNPs “find” the alternative exon, that is, an exon that, unlike 
constitutive exons, is not always included in the mature transcripts from that particular gene.  
Exon recognition is influenced by different factors, including RNA polymerase II transcriptional 
elongation rate, which is now established to be anti-correlated with splicing efficiency (de la Mata et 
al., 2003; Dujardin et al., 2014; Moehle, Braberg, Krogan, & Guthrie, 2014).       
In addition, exon recognition, and thus splicing regulation, is carried out by cis elements, i.e. 
regulatory sequences located in the vicinity of the alternative exon, and by a group of trans acting 
regulators, which are proteins that alone or with interacting partners bind to the cis elements, to 
promote, or else to inhibit, the recruitment of the spliceosome machinery proteins to the alternative 
exon splice sites (Figure 1.3B). The cis elements are of four types: exonic splicing enhancers (ESEs), 
exonic splicing silencer (ESSs), intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs). 
The trans regulators are proteins that are classified as splicing factors and that may enter in the 
classification of RNA-binding proteins (RBPs) if they establish direct protein-RNA interactions. The 
two main families of alternative splicing trans regulators are the serine/arginine-rich proteins (SRs) 
and the heterogeneous nuclear ribonucleoproteins (hnRNPs). However, there are several dozens of 
splicing factors known, some of which are tissue-specific, whose targets events of alternative splicing 
have been uncovered. RBP-regulated alternative splicing events have been discovered through the 
study of transcript changes in gene knock-out models or RNA silencing experiments, but also by 
biochemical methods like cross-linking-immunoprecipitation sequencing, or CLIP-sequencing, which 
allow the transcriptome-wide detection of direct protein-RNA interactions. This is the case of 
proteins like NOVA, important during neural differentiation (Licatalosi et al., 2008), RBFOX1-3 and 
PTBP1, relevant during development and in adult tissues, like the brain or muscle (Y. I. Li, Sanchez-
Pulido, Haerty, & Ponting, 2015)(Weyn-Vanhentenryck et al., 2014), or QK in myogenesis (Hall et al., 
2013). 
From these studies new ideas emerged about alternative splicing control. An important one is that 
alternative splicing is context dependent. Indeed, several examples showed that what determines if 
the splicing factor will have an activating or suppressive role on the decision to include an exon in 
the mature transcript is not necessarily the cis-element sequence, but rather the position where it 
stands (Figure 1.3C). As a result, it has now become an important goal for alternative splicing 
researchers to establish what is called an RNA-binding map for each RNA-binding splicing factor, 
which can be mainly accomplished by experimental designs that include CLIP-sequencing 
technology, but that has also been attempted in silico, namely through motif-enrichment 
approaches (Park, Jung, Rouchka, Tseng, & Xing, 2016; Paz, Kosti, Ares, Cline, & Mandel-Gutfreund, 
2014). Importantly, this kind of studies have been helped by the publication of a list of RNA-binding 
motifs for a total of 204 RBP coding genes from 24 eukaryotic species generated by the work of Ray 
and collaborators (Ray et al., 2013),  who through biochemical assays and computational analysis 
elucidated the combinations of 7-nucleotide spanning RNA nucleotides better suited for binding of 
each RBP.  
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Figure 1.3 – Splicing reaction and splicing regulation. (A) Two-step pre-mRNA splicing reaction or event of splicing. (B) Splice 
site choice is regulated through cis-acting splicing regulatory elements (SREs) and trans-acting splicing factors. Based on 
their relative locations and activities, SREs can be classified as exonic or intronic splicing enhancers and silencers (ESEs, ISEs, 
ESSs or ISSs). These sequences recruit splicing factors to promote or inhibit recognition of nearby splice sites. Common 
splicing factors include SR proteins and hnRNPs, which assist U2 and U1 snRNPs during spliceosomal assembly. (C) 
Characterized examples of context-dependent alternative splicing regulation by SREs and four splicing factors. B and C 
panels of this figure are adapted from (Matera & Wang, 2014).) 
1.2.2 Alternative Splicing and Its Different Forms 
Different types of alternative splicing events have been described, according to the relative position 
the included or excluded regulated exon has in relation to the competing splice sites and also the 
way it is annotated itself (Figure 1.4). The seven possible alternative splicing event types are: (1) 
skipped exon (SE), which involves an exon flanked as usual by two introns (a “cassette” exon); (2) 
mutually exclusive exons (MX), where a choice is made to retain either one of two “cassette” exons; 
(3) retained intron (RI), the possibility that the spliceosome reads-through an intron, thereby 
keeping it in the final transcript; (4) alternative 5’ splice site (A5), in which there is competition for 
spliceosome recruitment between two 5’ splice sites of an intron; (5) alternative 3’ splice site (A3), 
equivalent to the 5’ splice site case in which either of two competing 3’ splice sites will be used; (6) 
alternative first exon (AF) that involves the inclusion of one out of two concurrent first exons; and (7) 
alternative last exon (AL), related to the inclusion of one out of two concurrent last exons. The AF 
type of alternative splicing is usually not directly linked to spliceosome regulation, since the choice of 
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the first exon incorporation into a transcript is made through alternative transcription initiation 
sites. 
1.2.3 Quantification of Alternative Splicing 
Alternative splicing quantification can be done using as measure a relative ratio of the levels of 
transcripts that include a regulated exon over the levels of transcripts that do and do not include it. 
In this form, alternative splicing quantification assesses the rate of selection by the spliceosome of a 
pair of splice sites over an alternative pair.  
Alternative splicing can be measured from relative abundances of transcript isoforms obtained 
through single gene transcripts PCR, or through high-throughput, multi-gene encompassing 
methodologies, like expression microarrays and RNA-sequencing. RNA-sequencing technology offers 
great advantages over nucleotide probe hybridization techniques because, by giving access to the 
actual mRNA sequence, it allows to distinguish very similar transcripts, including new ones, apart 
from easily providing accurate measurements of mRNA species abundance across a larger range of 
expression. 
1.2.3.1 A note on next-generation sequencing transcriptomics  
The designation next-generation sequencing refers to a group of technologies of nucleotide 
sequencing, namely of DNA, which, from millions of different DNA species (molecules) that are 
attached to a solid phase structure and physically compartmentalized, allow to follow this same 
number of sequencing reactions individually.  
Figure 1.4 – Alternative splicing event types. White-and light rose-filled boxes represent alternative exons. InN the cases of 
A3 and A5 event types, the alternative white segment of the transcript forms a larger exon with the flanking exon fragment. 
Scheme is adapted from (Alamancos et al., 2014). 
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Next-generation RNA-sequencing (RNA-seq) is usually run on DNA molecules that have their 
complementary sequences, called complementary DNA or cDNA, and which are produced by an 
enzyme called reverse transcriptase that from the RNA molecule template synthesizes the 
corresponding DNA molecule. The initial step of an RNA-seq experiment thus consists of, from a 
population of total RNA or mRNA from a biological sample, produce an equivalent copy of cDNA 
molecules.  
The most commonly used next generation sequencing technique, commercialized by the company 
IlluminaTM, is based on the sequencing by synthesis principle, and is going to be briefly described. It 
starts with a step of fragmentation of RNA molecules into pieces of similar sizes, under 1000 bp long, 
identifying all fragments from the sample with a nucleotide sequence that includes a sample 
barcode, oligonucleotide primer sequences and an adapter to promote the attachment of the DNA 
fragments to the solid state sequencing unit. This pool of DNA fragments coming from one sample is 
then amplified by PCR, after which it is called a sequencing library. This library is then hybridized to a 
flat surface called a flow cell that contains millions of binding sites for the attachment of unique DNA 
fragments. DNA sequencing is finally carried out in aqueous phase, using DNA polymerase enzymes 
and each of the four DNA nucleotides tagged with a particular fluorophore. These nucleotides have a 
chemical group that prevents more than one nucleotide to be added to the nascent synthesized DNA 
molecule at a time. Therefore, the addition of each nucleotide is followed in a controlled way by 
capturing a fluorescence signal, then the chemical group is released and the DNA synthesis resumed 
with addition of new fluorophore-tagged nucleotides. 
The sequencing results come in a file that contains nucleotide sequences of each of the molecules 
synthesized in the flow cell, each of which will make a sequencing read, and can then be used for 
downstream analysis. Namely, using specialized software to carry out this analysis, reads coming 
from an original mRNA sample can be aligned to a reference genome, and these data can be used for 
quantification of exons, introns, transcripts and genes in the original sample. Quantified features are 
presented in individual files and are called raw counts (i.e. the raw number of reads mapping to a 
feature). 
1.2.3.2 The Percent Splicing index 
The above mentioned alternative splicing metric that expresses the relative frequencies at which the 
spliceosome efficiently splices an alternative exon in order to incorporate it in the mature mRNA 
molecule takes the name of percent splicing index, percent-spliced in, PSI or ψ (Venables et al., 
2008; E. T. Wang et al., 2008). The general formula of PSI calculation for an event of alternative 
splicing affecting one gene, and given a group I of transcript isoforms that include the stipulated 
alternative exon and a group E of transcripts in which this exon is not spliced, is as follows: 
𝑃𝑆𝐼 =  
∑ 𝑁𝑢𝑚𝑏𝑒𝑟 𝐼𝑛𝑐𝑙𝑢𝑠𝑖𝑣𝑒 𝑇𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑖𝜖𝐼
∑ 𝑁𝑢𝑚𝑏𝑒𝑟 𝑇𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑛𝑛𝜖𝐼∪𝐸
, 
and takes values from 0 to 1. 
While using RNA-seq data, the way transcript numbers are estimated varies according to the 
software algorithms and options used. The transcripts considered may come from a previous 
reference annotation of the genome or else assembly of new transcript isoforms may be allowed 
during the analysis. Not only that, PSI values can in practice also be calculated from numbers of 
sequencing reads that span the exon-exon junctions involved in the alternative splicing event, or the 
reads that span both the exon-exon junctions and the alternative exon individually. This way of 
computing PSIs is called event-centric, in contrast to the isoform-centric that departs from counts 
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relative to the whole transcript isoform. The work presented here makes use of the isoform-centric 
approach.    
1.3 ALTERNATIVE SPLICING IN GLIOMA 
Alterations of alternative splicing patterns have been extensively reported to promote or help 
sustaining tumourigenesis. In 2007, a first publication showed how a change in the expression of a 
splicing factor could cause malignant transformation (Karni et al., 2007). In this work it was shown 
that fibroblasts overexpressing SRSF1 protein induced tumour formation through transplantation in 
a mouse model, with that overexpression producing switches in the relative abundances of 
oncogenic and tumour suppressive transcript isoforms that explained the malignant behaviour. 
More recently, already with the use of RNA-seq data, namely coming from the large cohorts of the 
TCGA project, pan-cancer studies have documented the existence of alternative splicing patterns 
that are cancer- and also cancer-type specific (Danan-Gotthold et al., 2015; Sebestyén, Zawisza, & 
Eyras, 2015; Tsai, Dominguez, Gomez, & Wang, 2015).   
There are already descriptions of recurrent alternative splicing alterations in glioma, mainly in 
glioblastoma. In terms of known splicing factors implicated in this disease, there are PTBP1, PTBP2, 
A2BP1 (RBFOX1) and MBNL1. Although only PTBP1, and not PTBP2, gene expression alterations have 
been detected in tumour samples or glioma cell lines, it was shown by Cheung and collaborators that 
the down-regulation of these proteins in glioma cell lines had an onco-suppressive effect, reducing 
cell division rhythms and cell migration with a contrasting increase in cell adhesion (Cheung et al., 
2009). Microarray expression analysis revealed that PTBP1 expression reduction promoted the 
inclusion of exon 3 of the RTN4 gene, thus leading to the expression a protein that reduced cell 
proliferation. In another study a new important target of PTBP1 splicing regulation was discovered: 
the tumour suppressor annexin 7 gene (ANX7) (Ferrarese et al., 2014). Once again, an alternative 
exon silencing role for PTBP1 was found in glioblastoma cells, where the inclusion of ANX7 exon 6 
transcripts was suppressed resulting in decreased targeting of the EGFR growth factor receptor for 
degradation. Another well-studied example of the impact of splicing factors in glioma is that of the 
A2BP1 protein. Usually expressed in differentiated cells from the neuronal lineage, this protein was 
found to be downregulated in glioblastoma, resulting in a compromised terminal differentiation and 
acquisition of tumorigenic properties of neural stem cells (Hu et al., 2013). In this work, TPM1, a 
cytoskeletal remodelling protein, was found to be a crucial target of A2BP1, whose lack of splicing 
contributed to the malignant transformation.     
Then, many other examples of splicing events that specifically affect glioma have been studied, some 
of which will be described. Growth factor receptor FGFR1 gene codes for two protein isoforms,  
and this latter one missing exon 3 that encodes an extra NH2 extracellular loop that leads to a 
higher affinity towards the ligand and thereby to increased GBM cell growth (Yamada, Yamaguchi, 
Brown, Berger, & Morrison, 1999). FGFR1 was found to be upregulated in glioblastoma, with 
concomitant switch of the prevalent FGFR1 isoform to the form (Yamaguchi, Saya, Bruner, & 
Morrison, 1994). Another growth factor receptor, EGFR, which is the most mutated gene in 
glioblastoma and usually appears overexpressed in this tumour, has been shown to have splice site 
mutations for exons 2 and 22, although these mutations are not among the most frequent (Brennan 
et al., 2013). 
A final interesting example of a gene whose alternative splicing ratios greatly impact on glioma 
patient prognostic outcome prediction is the Reversion-inducing Cystein-rich protein with Kazal 
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motifs (RECK) gene. Until recently, only one protein isoform for this gene was known, with tumour 
invasion, angiogenesis and metastasis suppressive properties, through the downregulation of the 
extracellular matrix degrading metalloproteinases MMP-9, MMP2 and MMP14. A recent study 
(Trombetta-Lima et al., 2015) has shown the existence of two novel isoforms for RECK: RECK-B and 
RECK-I. Furthermore, this study shows that patients with their high-grade gliomas having higher 
ratios of the RECK transcript that encodes the canonical isoform are associated with a better overall 
survival. Experiments performed in vitro showed directly the oncogenic function of the RECK-B non-
canonical isoform, whose predominant expression in glioma cell lines promoted anchorage-
independent cell growth.     
This thesis project aims at analysing the contribution of alternative splicing regulation to the 
definition of glioma grades 2 to 4. It will have as a focus the glioblastoma (GBM) and low-grade 
glioma (LGG) RNA-seq data sets from the TCGA portal.  
Three main subjects will be approached. Firstly, an evaluation about whether a signature of 
alternative splicing that is exclusive of this layer of mRNA processing exists or rather if it is associated 
with the already defined glioma subtypes will be made.  
Then, the prognostic value of alternative splicing in glioma will be assessed and, specifically, genes 
and events of alternative splicing that make good glioma prognostic markers will be identified, 
particularly in terms of adding prognostic value to the already known glioma clinical and molecular 
risk factors.  
Finally, an attempt to identify potential mechanisms of alternative splicing regulation in trans, 
underlying the patterns of alternative splicing in the different samples analysed, will be made. 
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 METHODS 
2.1 DATA SETS 
Clinical (patient- and biospecimen-related) and transcriptomic data used in this manuscript were 
retrieved from the data portals of TCGA (“The Cancer Genome Atlas - Data Portal,” 2016) and GTEx 
(“GTEx Portal,” 2016).  
Patient and Biospecimen data files from the two glioma TCGA cohorts – Glioblastoma multiforme 
(GBM) and Low Grade Glioma (LGG) – included patient clinical registry information, as well as follow-   
-up data, and detailed information about sample quality, processing and full code nomenclature to 
enable correct assignment of gene expression data files to tumour case. As dictated by the sample 
management protocols of the project, all samples entering the cohorts contained at least 70 % 
tumour nuclei and not more than 50 % necrosis. Samples were subjected to histological 
classification, including WHO grade. A description of the nomenclature used to refer to the different 
histological types throughout this work is made in Table 2.1.  
Table 2.1 – Nomenclature code used for the different sample types of diffuse gliomas of the GBM and LGG TCGA cohorts.  
Official Designation This 
manuscript’s 
Designation 
Acronym Histology ICH id* WHO 
grade 
Diffuse Astrocytoma Low-grade 
glioma grade 2 
LGG2 9400/3 II 
Anaplastic astrocytoma Low-grade 
glioma grade 3 
LGG3 9401/3 III 
Glioblastoma   Glioblastoma 
multiforme 
GBM 9440/3 IV 
Diffuse Oligodendroglioma  Low-grade 
glioma grade 2 
LGG2 9450/3 II 
Anaplastic oligodendroglioma Low-grade 
glioma grade 3 
LGG3 9451/3 III 
Oligoastrocytoma Low-grade 
glioma grade 3 
LGG3 9382/3 II/III 
* Morphology code coming from the International Classification of Diseases for Oncology. 
In turn, a summary of clinical and molecular characteristics of glioma samples is shown in Table 2.2.  
RNA-seq expression data of level 3 from the same glioma cohorts referred above, processed and 
released by TCGA version 2 pipeline (“RNASeq Version 2 - TCGA - National Cancer Institute - 
Confluence Wiki,” 2016), was acquired on 14/09/2015. That pipeline includes mapping of 
sequencing reads to the TCGA, UCSC-nomenclature based, annotation (https://tcga-
data.nci.nih.gov/docs/GAF/GAF.hg19.June2011.bundle/outputs/TCGA.hg19.June2011.gaf) of the 
hg19 human genome assembly, using MapSplice (K. Wang et al., 2010) and quantification of 
expression using RSEM (B. Li & Dewey, 2011). Tables with raw gene and isoform counts, as well as 
normalized TPM (Transcripts per million ((B. Li, Ruotti, Stewart, Thomson, & Dewey, 2010)) for genes 
and isoforms, were used in different analyses.  
Data associated with GTEx tissue donor subjects and biospecimens consisted of sample tissue 
identity and subject and sample tissue identifiers. Samples used were a total of 8555, relative to 31 
different tissues from the human body, coming from 573 donors (Lonsdale et al., 2013).  
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Similar to what was previously described for TCGA transcriptomics data acquisition, RNA-sequencing 
expression data from the GTEx project was obtained as tables with raw and normalized (RPKM) read 
counts for genes and isoforms, on 06/01/2016 (project’s data release version 6). The pipeline used 
for RNA-sequencing analysis included sequencing read mapping to a modified version of Gencode 
v12 annotation of the hg19 genome assembly: 
http://www.broadinstitute.org/cancer/cga/tools/rnaseqc/examples/gencode.v12.annotation.patche
d_contigs.gtf.gz using TopHat (Trapnell, Pachter, & Salzberg, 2009) and quantification of known 
transcripts through the Flux Capacitor method (“GTEx Quantifications - Flux Capacitor - Confluence,” 
2016; Montgomery et al., 2010). 
Table 2.2 – Clinical and Molecular Characteristics of the TCGA Sample Set. 
Features Total Cases (N = 674) Publication 
Cohort 674 (700 samples)  
LGG  514 (Suzuki et al., 2015) 
GBM 160 (Brennan et al., 2013) 
WHO Grade   
II 250  
III 264  
IV 160  
DNA methylation 
Cluster Subtype 
  
LGm1 52  
LGm2 253  
LGm3 123  
LGm4 68  
LGm5 104  
LGm6 40  
Unknown 34  
Primary-
Recurrence 
Availability  
  
Sample Pair 
Available 
20  
Sample Pair Not 
Available 
654  
 
2.2 ANALYSIS OF ALTERNATIVE SPLICING DATA 
2.2.1 PSI data matrix generation  
Percent splicing-index estimates were calculated with SUPPA (Alamancos, Pagès, Trincado, Bellora, & 
Eyras, 2014) for alternative splicing events of the SE, MX, RI, A3, A5, AF and AL types by performing 
the ratio of the sum of the levels of a gene’s isoforms that include the regulated exon (or intron) 
over the sum of the levels of all the isoforms from the same gene. The alternative splicing events 
considered are generated by the program from the genome annotation provided and accounting for 
all splicing possibilities among the event types referred above. The definition of the regulated exon is 
done according to particular rules, specified in the software’s paper. 
A table of transcript isoforms quantified in TPM for the 700 GBM and LGG RNA-seq samples was 
assembled from individual patient files and used as input together with a TCGA genome annotation 
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gtf file. The two command lines of the software, generateEvents and psiPerEvent, were run with 
default parameters, as described in https://bitbucket.org/regulatorygenomicsupf/suppa/src.  
2.2.2 Preparation of working PSI matrices 
Resulting PSI tables were filtered for missing values, in order to eliminate very rare alternative 
splicing events and samples with generalized poorer quality of PSI quantification. A first filter 
removed alternative splicing events missing PSI calculations for more than 80 % of the samples, 
while a second applied filter excluded samples with missing values for more than 40 % of the AS 
events. Dimensions of PSI matrices for individual event types, as well as for a merged matrix 
containing all event types after missing values-filtering, are shown in Table 2.3. 
As a final step of PSI matrix preparation, duplicated samples pertaining to the same patient were 
removed (with the criterion of keeping as far as possible primary tumour samples only, rather than 
tumour recurrences), which resulted in a final PSI table containing 17151 alternative splicing events 
and 659 samples. 
Table 2.3 – Dimensions of PSI tables after filtering. 
 Alternative Splicing Event Type 
 SE MX RI A3 A5 AF AL All 
events 
Events (N) 10700 118 713 2093 1740 1553 234 17151 
Samples (N) 694 693 698 693 699 694 700 686 
 
2.2.3 Differential alternative splicing analysis 
Analysis of differential alternative splicing regulation across LGm subtypes was performed using the 
non-parametric Kruskal-Wallis statistical test for the equality of medians. This test can be applied 
when distributions of the variable under study are not normal, which is the case for PSI values 
(Rosner, 2011).  
A PSI matrix containing all 17151 alternative splicing events quantified for the 627 samples with 
known, LGm group was used (Ceccarelli et al., 2016). The Kruskal-Wallis test was applied through 
function kruskal.test, the Kruskal-Wallis test implementation from the R package stats, and, each 
alternative splicing event has been tested using a list of six PSI vectors, one per LGm group. 
Adjustment for multiple hypotheses testing was performed by the Benjamini & Hochberg False 
Discovery Rate (FDR) correction (Benjamini & Hochberg, 1995), using the function p.adjust from the 
R package base, and both Kruskal-Wallis test statistic and FDR values were kept for downstream 
analyses. 
For the selection of alternative splicing events showing a minimum PSI median difference between 
groups of 0.1, all 15 combinations of median differences between the six LGm groups were 
calculated for each of the 17151 alternative splicing events and, finally, events were selected if they 
had any of these differences reaching an absolute value of 0.1.     
2.3 ANALYSIS OF GENE EXPRESSION DATA  
Exploratory and differential gene expression analyses were performed using functions from 
Bioconductor packages edgeR (“edgeR: a Bioconductor package for differential expression analysis 
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of digital gene expression data,” 2016), which was created specifically for assessment of differential 
expression from count data such as RNA-seq, and limma (Ritchie et al., 2015). 
2.3.1 Preparation of working gene expression matrices 
A gene expression matrix was assembled from the 659 individual sample files containing gene raw 
read counts for the 20531 genes included in the TCGA genome annotation.  
For performing exploratory analysis, the referred matrix  was used together with a vector of tumour 
grade identifiers and a matrix of gene identifiers to create an edgeR-specific DGEList object type. 
Then, a filter for lowly expressed genes was applied: genes having more than 1 cpm (counts per 
million) in at least 160 samples, the sample size of the smallest group considered (the GBM 
samples), were kept in the DGEList, a criterion suggested in the edgeR user guide with the rationale 
that it guarantees that any gene in the analysis can only be considered differentially expressed 
between groups if consistently detected with a good signal in all samples from at least one group. 
The resulting matrix had 15189 genes. Read count normalization was carried out running the 
command calcNormFactors, with default settings, which performs a normalization of count data, 
taking into consideration samples library sizes and library compositional differences. Sample 
compositional differences are accounted for through the application of the trimmed mean of M-
values (TMM) method (Robinson & Oshlack, 2010), which estimates scaling factors for the library 
sizes (and thus for the total RNA output of each sample) that will minimize the log-fold changes 
between samples for most genes.  
edgeR uses negative binomial distributions to model the read counts from each gene in a library, the 
expected counts of the distribution being given by the parameter probability of success of finding 
the gene in the whole library multiplied by the library size. The biological coefficient of variation 
across samples for that expected count is given by the square root of the dispersion parameter of 
the negative binomial distribution. Dispersion estimates for each tag (gene) were calculated with the 
function estimateDisp and a design matrix built for the factor being considered: tumour grade. 
Specifically, using the command model.matrix, each sample took the value 1 for the level 2,3, or 4 to 
which it belonged to and zero otherwise. A detailed user’s guide for performing RNA-seq analysis 
using EdgeR can be consulted at the package’s page of Bioconductor website (“edgeR,” 2016). 
For differential gene expression analysis across LGm subtypes, the initially prepared table of raw 
RNA-seq read counts for the glioma samples, this time including only the 627 samples of known LGm 
subtype, was used together with a vector of sample LGm group identifiers and a matrix of gene 
identifiers to create a DGEList object. Then, a filter for lowly expressed genes was applied: genes 
having more than 1 cpm in at least 40 samples, the sample size of the smaller group under study, 
were kept in the DGEList. The resulting matrix had 15957 genes. Read count normalization through 
the trimmed mean of M-values (TMM) method (see explanation at the beginning of this section) was 
carried out running the command calcNormFactors, with default settings. 
Dispersion estimates were calculated and a design matrix built for the factor in study: LGm 
affiliation, following the same procedures already described.  
2.3.2 Differential gene expression analysis 
Given the DGEList object (containing (1) a raw count table, (2) a gene list, (3) sample normalization 
factors and (4) gene-specific dispersion estimates) and the design matrix, negative binomial 
generalized linear models were fitted to the expression estimates for each gene, using function 
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glmQLFit. Then, a one-way ANOVA-like empirical Bayes quasi-likelihood F-test to detect genes 
differentially expressed between any of the subtypes was carried out, using the glmQLFTest function 
over the output models and a contrast matrix consisting of the five pairwise comparisons between 
LGm groups 1,2,4,5,6 and LGm3. To get a summary table of the results, the topTags function was 
used. 
Differential gene expression was considered for genes whose F-test for the equality of expression 
between all LGm levels returned an adjusted p-value below 0.01 and that in addition had a log2-fold 
change of at least 1 in relation to the least malignant LGm subtype: LGm3. 
2.4 EXPLORATORY DATA ANALYSIS 
2.4.1 Alternative splicing vs Gene expression correlation analysis 
The strength of dependence of splicing ratios on the levels of transcriptional output was assessed 
using rank-based two-sided Spearman correlation tests for each vector pair of PSIs and 
corresponding gene expression levels (in counts per million or cpm). These tests were run using 
function cor.test from stats CRAN R package. A visual inspection of the relation between PSIs and 
cpms for selected events was made using the scatter plot function smoothScatter from the CRAN R 
package graphics. 
2.4.2 PSI variances 
Variances of quantification of each alternative splicing event within selected groups of samples were 
calculated with function var from CRAN R package stats and their distributions were visualized using 
functions densityplot and bwplot from CRAN R package lattice. 
2.4.3 Principal Component Analysis 
Principal Component Analysis of PSI matrices was performed using function PCA from the CRAN R 
package FactoMineR. For each alternative splicing event, PSI values were first subjected to centering 
around zero, using function stdize from the CRAN package pls. The PCA function was then run, 
without scaling, on the resulting matrix.   
The same functions were used for Principal Component Analysis of gene expression matrices. A table 
of read counts was exported in counts per million (cpm) from the respective edgeR-specific DGEList 
object and further log2-transformed using the voom function from R package limma. For each gene, 
expression levels in a logarithmic scale were then centered around zero and also not subsequently 
scaled when running PCA.   
Scores (samples) and loadings (events/genes) for each principal component were extracted from the 
“coord” matrix of “var” list and “ind” list, respectively. 
Sample scores for each principal component of interest were plotted using functions from the 
ggplot2 and gridExtra CRAN R packages.  
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2.5 FUNCTIONAL ENRICHMENT ANALYSIS 
In order to identify cellular pathways or biological processes strongly associated with DNA-
methylation subtype distinction or degrees of tumour malignancy, gene set enrichment analysis 
(GSEA) was used (Subramanian et al., 2005). This functional analysis in silico method is based on the 
expectation that, given a set of genes S belonging to a common functional category and a large list of 
genes L ranked according to the strength of association with the distinction of classes under study 
(e.g. according to statistical significance of differential expression between classes), the functional 
category represented by S will be relevant for this distinction if its genes accumulate in a biased, 
non-uniformly distributed, way at either of the extremities of the ranked L list. The measure of the 
relevance is given by an enrichment score (ES) that is the maximum absolute value attained by a 
running-sum statistic obtained along a random walk through the ranked L list, in which the statistic is 
incremented in steps involving genes from the gene set S in study and decremented otherwise. The 
significance of the test is assessed from a null distribution of the ES obtained by performing sample 
or gene permutations followed by ES calculations.  
GSEA was carried out using the GSEA-P application, kept by Broad Institute, using gene sets from the 
MSigDB database version 5.1, also maintained by the same institution, namely for KEGG pathways, 
Reactome pathways and Gene Ontology Biological Process terms. The pre-ranked analysis mode was 
run, without weighted steps for ES calculations and a minimum number of 15 genes from the gene 
set under test having to be present in the list under study. The metrics used for the analysis of 
functional category enrichment among genes/alternative splicing events that better differentiate 
LGm subtypes were the F-statistic and Kruskal-Wallis rank-test statistic as obtained from differential 
gene expression and differential splicing analysis, respectively. For the differentiation of levels of 
malignancy, the metrics used was principal component loadings for genes/events of alternative 
splicing, the module of the loadings having been used in the latter case. The enrichment of a gene 
set was considered significant when the associated FDR adjusted p-value was below 0.05. 
2.6 SUPERVISED SAMPLE CLASSIFICATION  
The PAM algorithm implemented in the pamr R package (Tibshirani, Hastie, Narasimhan, & Chu, 
2002) was run on the 17097 PSIs of non-zero variance across the 627 samples with assigned DNA-
methylation cluster subtype (LGm group). This supervised learning method relies on an approach 
called the nearest shrunken centroid classification. Nearest shrunken centroid classifiers function by 
computing, for each variable and for each class, a centroid which consists of a coefficient of variation 
(mean/standard deviation). Then when a sample class has to be predicted, the Euclidean distance 
from the values it takes for each variable to the corresponding centroids of each class is calculated 
and the sample gets assigned to the closer class. The PAM algorithm includes an extra feature, which 
is a shrinkage procedure, which consists of picking a number of values and subtracting them one at a 
time from each class centroid. At each step the classifier will be revaluated by cross-validation, to 
check for the shrinkage value that generates less prediction error. Some genes are eliminated from 
the classifier due to shrinkage and, since the lowest error level classifier typically has a non-zero 
shrinkage, it will consist of a subset of the initial variables submitted to build it. The steps of this 
analysis included a training step, run through the command pamr.train, a cross-validation step, run 
by the function pamr.cv, and a final FDR estimation for all the classifiers at multiples shrinkages, 
using pamr.fdr. Finally, the classifiers chosen were in each case (for each training set used) the one 
producing fewer errors on cross-validation and its list of classifying genes compiled using the 
pamr.listgenes function. 
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h(t) = h0(t) exp(β1 x x1 + …+ βi x xi + …+ βk x xk), 
2.7 SURVIVAL ANALYSIS 
2.7.1 Kaplan-Meier curves 
Kaplan-Meier survival curves are built through calculation of survival functions, i.e. probabilities of 
survival up to a given time. These survival values are usually obtained using the Kaplan-Meier 
estimator, which consists of, for each time t, multiplying the conditional probability of surviving up 
to time t given that one survived until time t-1 by the survival value at time t-1 (Rosner, 2011). In 
these calculations, the conditional probabilities for survival at each time are obtained excluding 
patients that were censored during the last time interval between collections of patients’ follow-up 
data. Survival curves were created by plotting values of the survival function for the different strata, 
obtained with the help of CRAN R package survival. First, a Surv object was created with patient 
right-censored overall survival data. This object was then passed to the survfit function using a 
categorical factor vector as the formula to specify the different patient strata. Survival curves were 
plotted using standard functions. 
2.7.2 Cox regression models  
With the aim of finding the relationship between patient’s overall survival and exposure to certain 
factors, namely increasing levels of gene expression or PSI values for an alternative splicing event, 
Cox proportional-hazards models were used (Prentice, 1992). These models allow to estimate the 
ratio between the hazards, i.e. the instantaneous probability of an event (e.g. a death event) at time 
t+Δ, given survival until time t, of two subjects that differ by one unit of exposure to a potentially 
impactful variable on survival. The Cox proportional-hazards models are regression models with the 
following general formula, given a set of explanatory variables k: 
where h0(t) and h(t) are the hazards at time t of having, respectively, a baseline value for the k 
independent explanatory variable(s) and a baseline value incremented of xi units for the same 
variable(s). The coefficient βi represents the hazards ratio for each particular explanatory variable 
or risk factor and is assumed to remain constant throughout time in order for the application of 
these models to be reliable. The null hypothesis that each βi is equal to zero vs the alternative 
hypothesis that it is different from zero can be tested using the test statistic Z = βi /se(βi) and 
conducting a two-sided significance level α test. Confidence intervals for the βi estimation can be 
given by (ec1, ec2), where c1 = βi – z1-α/2se(βi) and c2 = βi + z1-α/2se(βi), with z1-α/2  corresponding to 
the quantile of probability 1-α/2 of a standard normal distribution (Rosner, 2011).. 
Cox models to study the value of various independent variables on patient’s overall survival were 
derived using function coxph from the survival package on a Surv object, built as specified above. A 
description of the main generated models is presented in Table 2.4. 
The levels of nominal risk factors for each patient were specified using categorical, factor class, 
vectors with levels designations, while the levels of continuous risk factors were specified as numeric 
vectors. Principal component sample scores, as well as PSI values, were used directly for Cox-model 
derivation. Gene expression levels were used in logarithmic scale, a procedure shown to perform 
correctly in a paper that compared several transformation and scaling methods for application to 
RNA-seq data for Cox model creation purposes (Zwiener, Frisch, & Binder, 2014).  
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Table 2.4 – Description of the main Cox proportional-hazards models derived. 
Variable(s) Model equation  
Gene expression PC1 sample score h(t) = h0(t ) exp(βPC1 x PC1 sample score) 
Gene expression PC2 sample score h(t) = h0(t ) exp(βPC2 x PC2 sample score) 
WHO grade h(t) = h0(t ) exp(βGrade x Grade) 
Gene expression level h(t) = h0(t ) exp(βGene x GElevel) 
Percent spliced-in ratio (PSI) h(t) = h0(t) exp(βASevent x PSI ) 
Percent spliced-in ratio and Gene expression 
level 
h(t) = h0(t ) exp(βGene x GElevel + βASevent x PSI) 
Age at diagnosis h(t) = h0(t ) exp(βAge x Age) 
DNA-methylation cluster h(t) = h0(t ) exp(βDNAmetclustx DNA_met_clust) 
Percent spliced-in ratio, Gene expression 
level, DNA-methylation cluster, Grade and 
Age 
h(t) = h0(t ) exp(βGene x GElevel + βASevent x PSI + βDNAmetclustx 
DNA_met_clust + βGradex Grade + βAgex Age) 
Gene expression level, Grade and Age  h(t) = h0(t ) exp(βGene x GElevel + βGradex Grade + βAgex Age) 
Gene expression level, Percent spliced-in 
ratio, Grade and Age 
h(t) = h0(t ) exp(βGene x GElevel + βASevent x PSI + βGradex 
Grade + βAgex Age) 
 
2.7.3 Venn diagrams 
Venn diagrams were produced using a specific tool for that purpose, produced by the Girke Lab  
(“Graphics and Data Visualization in R,” 2016), whose R script is available at the URL 
http://faculty.ucr.edu/~tgirke/Documents/R_BioCond/My_R_Scripts/overLapper.R. This script 
requires as input a list of vectors corresponding to the sets to enter the diagram and diagrams are 
produced using the vennDiagram function from the limma package.   
2.8 STUDY OF ALTERNATIVE SPLICING REGULATION IN TRANS 
2.8.1 Correlations between RBP gene expression and exon inclusion levels  
Analyses of the correlation between alternative splicing event PSIs and RBP gene expression levels 
were performed as described in 2.4.1, except that the gene expression measurement unit used was 
TPM. Only samples having a minimum RBP gene expression level of 1 TPM were used. The 
concordance between correlation test results for the GTEx and TCGA datasets was made through 
plotting the logarithm of the correlation test FDR adjusted p-values for the alternative splicing 
events common to the two datasets, with log-FDR values relative to negative correlations being kept 
negative and those relative to positive correlations taking a plus sign.  
2.8.2 Mapping of RBP binding motifs along the genome using FIMO 
Binding motifs for 224 RBPs have been identified in this work (Ray et al., 2013), each one having 
been represented as a 7-mer (7 nucleotides long) position-specific scoring matrix (PSSM), which is a 
way of defining biological patterns that allows for different levels of nucleotide degeneration across 
the positions defining the motif. As such, for a seven nucleotides long motif, a PSSM matrix has four 
rows representing each nucleotide and seven columns representing each position of the motif, while 
the values of the matrix are probability scores that determine the frequencies at which a nucleotide 
appears at each position of this particular motif. In the particular case of the RNA binding motifs 
described in this paper, these sequences were identified by protein-RNA competition assays, and so 
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PSSM scores reflect binding preferences for each RBP. These PSSM for each RBP of interest were 
used by the FIMO tool from the MEME suite for motif analysis to map motif occurrences along the 
human genome. The fimo command was run using as input files motif PSSMs in MEME format and 
the hg19 genome sequence in FASTA format, and default options, except for a p-value threshold of 
1x10-3.  
2.8.3 Quantification of putative alternative splicing event targets for different RBPs 
Identification of putative target alternative splicing events for the RBPs of interest was done through 
selecting those containing binding motifs identified by FIMO at a p=1x10-3 threshold and having their 
splicing ratios correlated with RBP gene expression in both glioma TCGA and multitissue GTEx 
datasets at an FDR cut-off of 0.01. 
2.8.4 Definition of regulatory regions for RNA splicing map generation 
Eight regulatory regions were considered for the general exon-skipping alternative splicing event. 
Relevant features taken into account were the alternative/regulated exon, its two flanking introns 
and the upstream and downstream constitutive exons (Figure 2.1). Given these, segments of 150 bp 
of intronic sequence flanking the three exons as well as of 50 bp of exonic sequence spanning the 
beginning and end of these exons were considered. These lengths implied a minimum intron length 
of 300 bp and a minimum exon length of 100 bp in order for regulatory sequences not to overlap. 
The length of the segments was chosen based on literature reviewing to find the most usual relevant 
positions described in RNA splicing maps. However, a compromise was made between using 
genomic segments long enough to likely contain splicing regulatory sequences and short enough to 
avoid excluding too many events from the analyses due to exon or intron length limitations.  
 
Figure 2.1 – Definition of regulatory regions for a general event of exon-skipping (SE).e1_E – exonic region corresponding to 
last 50 nucleotides of first constitutive exon; e1_I/s2_I – intronic region corresponding to first/last 150 nucleotides of intron 
located upstream from alternative exon; s2_E/e2_E – exonic region corresponding to first/last 50 nucleotides of alternative 
exon, e2_I/s3_I – intronic region corresponding to first/last 150 nucleotides of intron located downstream from alternative 
exon; s3_E – exonic region corresponding to first 50 nucleotides of second constitutive exon  
2.8.5 Determination of the best correlation test and motif binding threshold parameters for 
generating each RNA splicing map  
Identification of likely targets of RBP action was based on the detection of events of alternative 
splicing whose PSIs correlated with RBP abundance and that effectively contained RBP binding 
motifs in their regulatory regions.   
To select the group of significantly correlated alternative splicing events, an FDR adjusted p-value 
threshold for the correlation between PSIs and RBP gene expression across samples was used. To 
define the group of RBP binding motifs, a p-value cut-off for the stringency of motif identification by 
FIMO was in turn used. Specifically for this latter, lower p-value thresholds were used for less 
degenerate and thereby less ambiguously detectable 7-mers, while higher p-value thresholds 
allowed the detection of 7-mer motifs defined by PSSM models reflecting looser combinations of 
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nucleotides. These two p-value parameters were allowed to change until maximum signal for RBP 
regulation was reached, as described below. 
Once having set these two parameters, a Fisher’s exact test for each of the eight regulatory regions 
was run, having as null hypothesis that alternative splicing events whose PSIs correlate with the 
expression of an RBP are independent of them containing in that regulatory region a binding motif 
for the same RBP. One-sided tests were performed to explore the alternative hypothesis that the 
proportion of alternative splicing events correlated with RBP expression is higher when binding 
motifs are present than when not. To distinguish between putative enhancing and silencing roles of 
the RBP binding to the regulatory region in the inclusion of the exon, tests for positively and 
negatively correlated alternative splicing events were performed separately, always having the 
group of events that did not significantly correlate with RBP expression as the null sample. To 
identify the alternative splicing events that contained at least one RBP binding motif for each 
regulatory region, firstly, genomic coordinates of both binding motifs mapped by FIMO and 
regulatory regions for the annotated splicing events were used to create “genomic range” R objects, 
and secondly, the overlap between the two features was checked. The representation of genomic 
ranges was implemented using function GRanges and range overlaps were obtained with function 
findOverlaps, both from the Bioconductor package GenomicRanges.   
Maximizing the significance of the Fisher’s tests referred above was achieved by trying series of 
different correlation FDR adjusted p-values and RBP binding motif p-values. These series 
corresponded to 5 % quantile steps of correlation FDR values and the 5, 20, 35, 50, 65, 80 and 95 % 
quantiles of FIMO p-values for the binding motif under consideration. To visually search for ranges of 
parameters that jointly and consistently appear to maximize the significance of the tested 
association, heat maps were drawn for each set of tests applied to each regulatory region for both 
positive and negative correlations, using function heatmap.2 from CRAN R package gplots. Two sets 
of parameters were selected to use in the generation of RNA splicing maps: the two that produced a 
lower p-value for each of two regulatory regions. This selection from two rather than one region was 
found useful to ascertain the robustness of the inferred map. 
Finally, using a single combination of correlation FDR adjusted p-value and motif p-value selected in 
the previous step, RNA splicing maps were based on the p-values of Fisher’s exact tests applied to 
each of the 800 nucleotide positions in the general alternative splicing event defined by the 
concatenation of the regulatory regions. Tests were made on 50 nucleotide-spanning sliding 
windows, centered in the position of interest. The RNA splicing maps were plotted with graphing 
functions from the ggplot2 package. 
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 RESULTS 
3.1 SIGNATURES OF ALTERNATIVE SPLICING IN GLIOMA 
This section will be dedicated to characterizing the overall patterns of splicing regulation in the 
studied glioma cohort. Departing from PSI matrices for a large set of alternative splicing events, 
exploratory analysis, namely using multivariate methods, will be performed, looking at how this data 
organize in relation to other clinical variables and molecular classifications, with particular focus on 
the comparison of PSI data with gene expression data. Subsequently, in order to identify the 
alternative splicing events that vary according to the pan-glioma DNA-methylation cluster subtype, 
along with potential trans-activators of these events, differential splicing and gene expression 
analysis between groups will be carried out and interesting new findings outlined. 
Data tables with alternative splicing event PSI values and gene expression levels used throughout 
this section represent 659 glioma patients, or 627 in analysis where DNA-methylation subtypes must 
be specified, as this classification was not available for the remaining 32. As for the alternative 
splicing events included in the analysis, these are a total of 17151, representing 7349 regulated 
cognate genes, of the types skipped exon, mutually exclusive exons, retained intron, alternative 3’ 
splice site, alternative 5’ splice site, alternative first exon and alternative last exon, as defined in the 
manuscript’s introduction and whose individual numbers are shown in the Methods section. 
Alternative first exon events, despite having a less clear and for sure weaker association with splicing 
machinery function, were nevertheless included in the present study given their potentially equally 
important contribution to gliomagenesis as the one given by the other event types. Gene expression 
data tables used contained 15189 or 15957 genes (see Methods). 
3.1.1 Determination of the level of dependence of alternative splicing on the expression of cognate 
genes 
Transcript levels for a given gene are good indicators of the overall abundance of transcripts that 
serve as the substrate for splicing machinery action, and can also work as an indirect indication of 
the rates of RNA synthesis, known to be relevant for splice site recognition by the spliceosome, 
namely when considering regulated splicing for which there is splice site competition.  
Since the main focus of this thesis is to evaluate the contribution of alternative splicing regulation in 
glioma, an identification of alternative splicing events clearly independent of gene expression was 
carried out. In order to determine the potential strength at which transcription influences 
alternative splicing, or the reverse, two-sided Spearman correlation tests between each splicing 
event PSIs and the levels of its corresponding gene transcripts were made.  
A big portion of the events had their PSIs correlated in a consistent way with their gene expression, 
11262 (66 %) and 9784 (57 %) out of 17151 having showed a significant Spearman correlation at an 
FDR below 0.05 and 0.01, respectively. However, as can be observed in the plot from Figure 3.1, 
significant events had correlation coefficients predominantly very low: minimum value of 0.09 at 
FDR < 0.05 and of 0.11 at FDR < 0.01, suggesting there is no strong mutual influence between 
transcriptional activity and splicing regulation in glioma samples. Considering an FDR cut-off of 0.05, 
there were still 5837 alternative splicing events (representing 3761 genes) whose regulation was not 
significantly correlated with their own gene expression. In terms of the sense of the association 
between gene expression and alternative splicing ratios, 55 % of the events had higher PSIs with 
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increased gene expression, and there were also more events showing positive correlation with gene 
expression among the ones with rho Spearman coefficients with an absolute value above 0.5 (63 %).   
Some of the top significant correlations corresponded to alternative first exon events, which are 
known to be highly linked to transcription initiation, rather than with splicing regulation. Events of 
these types account for only ~8 % of all the alternative splicing events studied but could be thought 
of as being a major contributor to the high proportion of statistically significant alternative splicing 
event-cognate gene expression correlations found. In order to understand if this was the case, 
quantification of significant correlations was redone this time including all event types other than 
alternative first and last exon types. Again, not only the majority of alternative splicing events 
showed a consistent correlation between their PSIs and gene expression, but the proportions of 
significant hits were exactly the same as detected when considering all event types: 10071 (66 %) 
and 8737 (57 %) out of 15364 events showed a significant Spearman correlation at an FDRs of 0.05 
and 0.01, respectively.  
3.1.2 Assessment of the extent of alternative splicing regulation/dysregulation in glioma 
The variance of PSI values detected for a given alternative splicing event indicates how strongly this 
is subject to regulation in a considered group of samples, and may therefore also reflect the 
potential for this event to allow tumour class/subtype stratification. To understand the extent of 
alternative splicing regulation in glioma, and in particular among alternative splicing events whose 
PSIs are determined mostly by other effects rather than their own gene expression, density plots and 
boxplots for PSI variances were drawn (Figure 3.2).  
 
Most alternative splicing events had PSI variances below 0.012 (standard deviation < 0.11), the 75 % 
quantile for all AS events, with a minority of events displaying a quite high PSI variance, going from 
0.031 (Q3 + 1.5 IQR) up to 0.200 (maximum value). The distribution of variance of the group of 
alternative splicing events whose PSIs were not (or were weakly) correlated with the expression of 
their cognate gene was overall lower than the one of the group of events for which this correlation 
was present (Figure 3.2). This observation suggested that in the former group of events there might 
then exist a lower proportion to be differentially spliced between glioma subtypes and thus be able 
Figure 3.1 – Correlation between PSIs of AS events and levels of gene expression of cognate genes Scatter plot of FDR of 
Spearman correlation tests vs correlation coefficient is shown. 
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to work as a good glioma subtype biomarker. The existence of a glioma alternative splicing signature 
that is independent of gene expression will be assessed below. 
An event’s PSI variance across tumour samples may also indicate the level of dysregulation of mRNA 
splicing in relation to normal tissue samples or, in the case of this pan-glioma study that does not 
include normal reference tissues, may indicate major differences in splicing machinery function 
between relevant tumour subtypes. For example, a glioma subtype could have the enhancing or 
suppressive role from an important splicing factor disrupted, or else the splicing machinery could 
have its efficiency affected at a particular level. This kind of alterations could potentially be detected 
through a change in the distribution of PSI variances in that subtype.  
Two particularly interesting glioma classification systems scrutinized for associations with this kind of 
dysregulation were tumour grade and DNA-methylation subtype (Figure 3.3-3.4). 
 
 
Figure 3.2 – Variance of AS events measurements in the TCGA glioma cohort. Density plots (A) and boxplots (B) of PSI 
variances for all 17151 AS events considered in this study (All), for 9784 events whose PSIs correlate with gene expression 
(PSIvsGE_Corr) and for 7367 events whose PSIs do not correlate or correlate more weakly with GE (PSIvsGE_NoCorr). 
Vertical dashed line in A represents the median variance value of 0.0029. Kolmogorov-Smirnov test for the null hypothesis 
the equality of the two distributions was used to assess statistical significance. *** - p-value<1x10-3. 
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Both along tumour grades and LGm groups, PSI variance distributions appeared similar overall. 
However, in the case of LGm subtypes some differences could be observed in the size of the low 
variance density peaks and the positions of the 75 % quantile. Indeed, LGm subtypes 2 and 3, 
together with samples of unknown LGm subtype, which were all GBM cases, had higher numbers of 
low alternative splicing event PSI variances, while LGm 1 and 6 subtypes displayed variance 
distributions predominantly with higher values (Figure 3.4). This overall behaviour showed by LGm1 
and LGm6 variances could indeed be the result of a loss of function of alternative splicing regulation, 
but could also arise from a higher intragroup molecular heterogeneity. 
Figure 3.3 – Variance of AS events measurements in the TCGA glioma cohort. Density plots (A) and boxplots (B) of PSI 
variances for all alternative splicing events considered in this study, in glioblastoma multiforme (GBM), grade III low grade 
glioma (LGG3) and grade II low grade glioma (LGG2) samples.  
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3.1.3 A portrait of gene expression and alternative splicing in glioma  
In order to understand how the two levels of transcriptomic data, gene expression levels and 
alternative splicing event PSIs, varied along glioma samples and specifically which clinical and 
molecular parameters contributed the most to that variation, principal component analysis (PCA) 
was used. This method was applied first to the full gene expression and PSI matrices, and 
subsequently to individual alternative splicing event types in order to identify possible differentially 
affected aspects of alternative splicing regulation in glioma.  
 
Figure 3.4 – Variance of AS events measurements in the TCGA glioma cohort. Density plots (A) and boxplots (B) of PSI 
variances for all alternative splicing events considered in this study, in samples from each of the six LGm subtypes. 
Kolmogorov-Smirnov test for the null hypothesis the equality of the two distributions was used to assess statistical 
significance. * - p-value<5x10-2,*** - p-value<1x10-3. 
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Figure 3.5 –  Principal Component Analysis scatter plots of gene expression in glioma.  Voom normalized, log2 counts per 
million of the 659 glioma cases and from 15189 non-zero variance expressed genes were analysed. Colour codes refer to 
eight different glioma classification systems, retrieved from TCGA metadata files and (Ceccarelli et al., 2016). 
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Figure 3.6 – Principal Component Analysis scatter plots of PSIs of the alternative splicing events measured in glioma.  PSIs of 
the 659 glioma cases and from 17097 non-zero variance alternative splicing events were analysed. Colour codes refer to 
eight different glioma classification systems, retrieved from TCGA metadata files and (Ceccarelli et al., 2016). 
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Figure 3.7 – Principal Component Analysis scatter plots of PSIs of the alternative splicing event types measured in glioma. 
PSIs from non-zero variance alternative splicing events were analysed. Colour codes refer to grade and DNA-methylation 
cluster sample assignment, retrieved from TCGA metadata files and (Ceccarelli et al., 2016). 
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Two-dimensional scatter plots of sample mappings along pairs of principal components explaining 
more than 1% of data variance each were inspected for the definition of sample clustering trends. In 
most cases, no distinct groups of samples were observed. Still, there was one principal component 
for each of the types of data looked upon that distributed samples in a quite consistent way along 
ordered tumour grades, from the least malignant grade 2 to the most malignant grade 4.   
Selected PCA plots along the most relevant principal components, coloured according to important 
clinical and molecular classification systems, are shown in Figures 3.5 for gene expression, 3.6 for all 
alternative splicing events and 3.7 for individual alternative splicing event types. 
Both gene expression and alternative splicing data are able to separate samples of WHO grade 2 
(LGG2 samples) from the ones of grade 4 (GBM), along principal components 1 and 2, respectively. 
Samples of grade 3 (LGG3) in turn appear spread along these dimensions, which as a whole creates a 
gradient that goes from the less malignant to the more malignant samples. Different DNA 
methylation subtypes all had some level or superposition along gene expression principal 
component 1 and alternative splicing principal component 2. However, subtypes LGm2 and LGm3 
formed a cluster that is well separated from another that included subtypes LGm4 and LGm5. 
Samples from subtypes LGm1 and LGm6 appear not to separate at all along the principal 
components shown and that have been inspected, which suggests the DNA-methylation markers 
used in the LGm epigenetic classifier to define these two subtypes are not strongly related with 
transcriptomic data. As for IDH mutation status, most wild type (LGm1-3) and mutant (LGm4-6) 
samples very evenly occupy two distinct hemi planes both in the gene expression and in the 
alternative splicing plots, with just minor outliers from both IDH-wild type and -mutated groups, 
which can be seen from the DNA-methylation cluster plot to correspond to samples from LGm1 and 
LGm6 subtypes. Adding the double chromosome arm deletion status to the colour code of the PCA 
plots highlights a trend for the samples with these copy-number variations to behave as a whole 
more differently in relation to IDH-wild type than samples without these chromosome deletions. The 
strata formed by the two IDH-mutant groups of samples are, to a certain extent, superimposable 
with the strata formed by LGm2 and LGm3 samples. From these four plots, it can be seen that the 
DNA-methylation glioma classification adds extra levels of information into the molecular distinction 
of samples, in a way that is quite independent from tumour grade classification. This classification 
incorporates the IDH mutation status and 1p19q-codeletion information, and is still able to 
discriminate within IDH-wild type and -mutant samples the groups LGm1 and LGm6, which in fact 
show a very heterogeneous behaviour.  
As for the similarities gene expression data have with the LGm classifier in terms of overall ability to 
discriminate glioma cases, as had been reported in the work of Ceccarelli and collaborators, in which 
a pan-glioma RNA-expression classifier was also developed (shown further down in Figures 3.5-3.6), 
it does not seem to capture the same levels of biological information, namely since it seems to be 
unable to distinguish any of the three IDH-wild type subgroups LGm3, LGm4 and LGm6. Alternative 
splicing separates the LGm subtypes very similarly to gene expression. 
The third rows of panels in Figures 3.5-3.6 highlight two glioma transcriptomic classifiers: one based 
on microarray gene expression data of glioblastoma cases only (Verhaak et al., 2010), and the pan-
glioma RNA-expression clusters classifier, developed in (Ceccarelli et al., 2016). Principal component 
1 but mostly principal component 2 of gene expression separate quite clearly most Proneural (PN) 
subtype samples from Neural (NE) ones, independently of tumour grade. Alternative splicing 
principal component 2 again separates these two groups, although with more overlap, similarly to 
gene expression principal component 1. Also very interestingly, the four LGr pan-glioma RNA-
expression clusters may be clearly observed in the gene expression PCA, along the first two principal 
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components, LGr 1 and 2 being two subgroups within the IDH-mutant-codel cases. Alternative 
splicing separates these groups as well as gene expression PC1 alone, and among its corresponding 
first six principal components neither reflected LGr1-LGr2 separations similar to the one obtained by 
gene expression PC2. 
Finally, in the histology panels of Figures 3.5-3.6, histological types can be seen to intermingle, 
except for glioblastoma samples that separate well from the remaining samples, as had been 
observed in the grade panel. In the proteome cluster panels, both gene expression and alternative 
splicing can be seen to be able to separate samples from the two clusters identified by the reverse-
phase protein lysate microarray platform.  
In this work, there will be a focus on tumour grade, a strong prognostic marker associated with 
malignancy of the tumour tissue, and in particular on the pan-glioma DNA-methylation cluster 
classifier, as it is based on a quite stable epigenetic mark, is useful to classify many different clinically 
relevant subtypes, both in terms of prognosis and therapeutic management of patients. A better 
understanding of the LGm subtypes in terms of important cellular and molecular pathways of 
disease development and progression would be desirable. Alternative splicing regulation may play 
key roles in some of these pathways or others more generalized in gliomas. 
In Figure 3.7, PCA scatter plots for individual alternative splicing event types are shown. Exon 
skipping plots are very similar to the plots for all events, due to the fact that this type of event is the 
most abundant: 10700 out of 17151 events. Compared to the other event types, skipped exon 
principal component 2 seems to form two more consistent LGm2 and LGm3 strata than alternative 
3’ splice site, alternative 5’ splice site and retained intron event types. Mutually exclusive exons 
made this separation more similarly to skipped exons and were also able to separate transcriptome 
subtypes and pan-glioma RNA-expression clusters through principal components 1 and 3, in a way 
that was very similar to the combination of the two first principal components of gene expression 
(data not shown). Curiously, from the alternative splicing event types shown in Figure 3.7, it was the 
only one mapping samples according to grade along the principal component 1, like for gene 
expression, instead of along principal component 2. Although PCAs for alternative first exons and 
alternative last exons are not shown, these also separated samples from the two transcriptomic 
classifiers similarly to gene expression along their principal components 1 and 3 or 1 and 4, 
respectively. These data suggest that these three types of alternative splicing are more dependent 
on gene expression, an association that would not have been anticipated for mutually exclusive 
exons. As a final note, although alternative last exon events, similarly to what happened to gene 
expression and mutually exclusive exons, separated tumour grades along the principal component 1, 
the same did not happen with alternative first exon events. This might indicate that the ability to 
separate more clearly transcriptome subtypes is not related with the absence of the principal 
component of variance found for most alternative splicing event types, which is a dimension that 
separates samples in way that does not reflect any known clinical or molecular factor.  
In order to try to assess if this principal component had a technical origin, a bias according to sample 
library size and sample source centre were checked for (Figure S2). In both cases, it was not possible 
to detect a source of bias, either through an accumulation of samples with a particular range of 
library sizes or with a particular source centre colour code on either side of PC1. Yet other possible 
factors behind alternative splicing first principal components were excluded, related with aneuploidy 
and mutational loads and quantification of tumour mass contaminations with cells from the immune 
system and stromal (general name for connective tissue) (Figure S3), which could be causing 
fundamental differences in the PSI quantifications. Information on these parameters was retrieved 
from (Ceccarelli et al., 2016) by separating the samples in two groups that approximately split the 
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variance along the principal component in two (principal component coordinates below and above 
0.05) and looking at the eventual presence of mutually exclusive values taken up by each groups for 
the different variables. There were no mutually exclusive ranges of values between the groups, 
although there was a trend for a higher immune cell abundance and percent aneuploidy in the 
samples with a high PC1 score. It is possible that these parameters are related with the first principal 
component of PSI event types skipping exon, retained intron, alternative 3’ splice site, alternative 5’ 
splice site and alternative first exon, but this would have to be investigated further.   
Finally, a very good separation between glioblastoma and low-grade glioma samples was obtained 
with alternative 3’ splice site PSI values (Figure 3.7), which might be linked to particular regulatory 
requirements for all or a subset of these events and is worth a careful analysis.  
3.1.3.1 Exploring the glioma alternative splicing signature 
Results from the previous section suggested alternative splicing contrasted samples in parallel ways 
to gene expression. But the similarity with which these two levels of transcriptomic data had 
structured samples could be a consequence of the inclusion in the alternative splicing analysis of 
events that were highly dependent on their own gene expression.  
In order to find if there was a glioma signature specific of alternative splicing, alternative splicing 
events whose PSIs were not significantly dependent on their own gene expression and whose range 
of PSIs varied to a reasonable extent across the samples cohort, so that differences between 
samples could be detected, were selected. These were then analysed by principal component 
analysis in order to identify main variance trends. Alternative splicing events with Spearman 
correlation FDR with their own gene expression above 0.01 and variance of 0.0225 (standard 
deviation = 0.15), as suggested for performing hierarchical clustering using PSI values in (“Percentage 
Splicing Index - Geuvadis MediaWiki,” 2016), were selected, making up a total of 795 events.  
Analysis of the first principal components associated with PSI values for these 795 events returned 
results that were very similar to the ones obtained using all non-zero variance 17097 events. 
Illustrating this point, two-dimensional scatter plots of sample mappings along PC2 and PC3 
obtained using these two sets of alternative splicing events, with tumour grade and LGm colour 
schemes, are presented in Figures 3.8-3.9.    
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Figure 3.8 – Principal Component Analysis plots made on all measured AS events. (A) and on variable AS events whose 
regulation is not dependent of gene expression (B). Colours are according to tumour grade. 
 
35 
 
 
Figure 3.9 - Principal Component Analysis plots made on all measured AS events. (A) and on variable AS events whose 
regulation is independent of gene expression (B). Colours are according to DNA-methylation subtype. 
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3.1.4 Functional Analysis of the gene expression and alternative splicing malignancy axes 
In the previous section it was shown that all gene expression and alternative splicing types had a 
principal component of variance along which samples from increasing tumour grade, and thus 
increasing malignancy, were mapped. A verification of whether these different axes ordered samples 
the same way was made, by looking at Spearman correlations between samples scores of the 
principal components of interest. Spearman’s correlations obtained are shown in Figure 3.10. 
 
Sample rankings were indeed very similar, with only mutually exclusive exons and retained introns 
presenting higher dissimilarities. This observation suggests there are coherent changes in 
transcriptional outputs along this therefore single dimension of glioma malignancy.  
In order to understand if there were coordinated gene expression and alternative splicing 
functionally relevant changes along these dimensions of variance, enrichment analysis on the gene 
expression PC1 and alternative splicing PC2 were performed for KEGG pathways, Reactome 
pathways and GO Biological Process terms. This was made by using the gene and event loadings 
from the principal components as the ranking metric for gene set enrichment analysis (GSEA) 
(Subramanian et al., 2005). This analysis would also help determine the extent to which gene classes 
defining the malignancy axes were coincidental in transcription and alternative splicing. 
Amongst upregulated pathways in more malignant samples (positive enrichment scores), there were 
immune response, cell cycle, extracellular matrix organization or cell-signalling, all of them pathways 
known to be important for tumour cell proliferation and invasiveness (Figure 3.11).  
Upregulated pathways in less malignant tumours included mostly neuronal cell lineage associated 
ones like neuroactive ligand receptor interaction, calcium signalling, long term potentiation, 
categories that likely reflect the fact that cells from lower grade tumours better resemble healthy 
glial cells, with neuronal functions preserved. 
Figure 3.10 –Spearman’s correlation coefficients for all pairwise comparisons of samples scores of malignancy-reflecting 
principal components  using skipping exon (SE), mutually exclusive exon (MX), retained intron (RI), alternative 5’ splice site 
(A5), alternative 3’ splice site (A3), alternative first exon (AF), alternative last exon (AL), all alternative splicing events (AS) 
and gene expression (GE). 
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Other examples were proliferation associated cell signalling pathways like ERBB2, Wnt, MAPK and 
muscle contraction associated pathways, which correspond to gene sets that have many calcium 
channels, also known to play a major role in normal astrocyte function. It is possible that some of the 
alterations detected reflect rather a downregulation in high-grade tumours in relation to both lower 
grade ones and healthy tissues. These results were consistent with the ones from Wang and 
collaborators, who detected cell cycle and Wnt signalling as main up- and down-regulated pathways, 
respectively, in grade 4 versus lower grade astrocytomas (Z.-L. Z. Wang et al., 2015).  
No gene sets were found enriched at an FDR cut-off of 0.05 for the splicing principal component 2 
event loadings. This can probably be explained by the fact that, unlike gene expression regulation, 
which is known to happen frequently through coordinate changes of the different players of a 
functional cellular pathway (e.g. signalling, metabolic), alternative splicing regulation is known to 
operate less frequently this way. This difference frequently leads to the impossibility to get biological 
insights into the impact of alternative splicing changes using tools as gene set enrichment analysis. 
Still, GSEA performed on KEGG pathways gene sets returned the lowest FDR of 0.09 (p-value of 
0.002) for the dilated cardiomyopathy gene set, containing genes involved in calcium channel 
transport (e.g. SLC8A1, ATPA2, CACNB4) and cell adhesion (e.g. ITGA6, ITGA3, LAMA2), biological 
functions that also appeared enriched in association with the gene expression malignancy axis 
(Figure 3.11). 
Figure 3.11 – Functional analysis of gene expression malignancy-reflecting principal component. Gene Set Enrichment 
Analysis using KEGG pathway gene sets on gene expression PC loadings was performed and selected functional categories 
at a FDR cut-off of 0.05 are shown.  
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Interestingly, enriched dilated cardiomyopathy genes were to a great extent different between gene 
expression and alternative splicing data sets. Namely, genes coding for different subunits of calcium 
transporters or integrins appeared either affected in terms of expression levels or of alternatively 
splicing, and members of the tropomyosin family (i.e. TPM1, TPM2, TPM3) appeared associated with 
different levels of malignancy only through alternative splicing changes.  
Because most genes whose alternative splicing varied the most along PC2 did not fit into functional 
categories represented by a given gene set, this analysis did not help in understanding if there was a 
great level of overlap between these and the genes contributing more to the gene expression PC1. In 
order to assess this question, the enrichment of alternative splicing events with high absolute value 
loadings among expressed genes that also had loadings with high absolute values was tested (Figure 
3.12).  
Although accounting for the 20 % of genes with more variance in alternative splicing and expression 
resulted in a significant enrichment at an α of 0.05, when only the 10 % genes that contributed more 
for variance across the two principal components were considered, this enrichment ceased being 
significant. These results attest for the conclusion that both gene expression and alternative splicing 
variation across glioma cases of different degrees of malignancy reflect important cell identities and 
functions, which are partially redundant between the two, but also partially exclusive.  
3.1.5 Analysis of differential gene expression across DNA-methylation cluster subtypes 
Before moving on into the identification of alternative splicing events regulated differently in the six 
glioma DNA-methylation groups, differential gene expression analysis between the same groups was 
performed. Knowing the genes more significantly altered across those conditions would be 
Figure 3.12 – Alternative splicing events and transcribed genes with higher loadings across the malignancy axis affect 
different sets of genes. Hypergeometric tests to evaluate the enrichment of genes affected by alternative splicing events that 
contribute the most to PC2 among the transcribed genes that also contribute the most to the gene expression PC1 were 
performed. Loadings thresholds corresponding to quantiles 0.80 and 0.90 were used for selection of alternative splicing 
events and transcribed genes with high contribution to the two principal components to enter in the statistical test. 
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interesting for comparison with the list of more differentially spliced genes. Furthermore, this 
analysis could allow to detect splicing regulators relevant in particular glioma subtypes. 
Differential expression analysis was carried out using the edgeR Bioconductor package, through 
fitting negative binomial generalized linear models for each gene and performing ANOVA F-tests for 
differences between the LGm groups. From a group of 15957 annotated genes consistently detected 
in glioma samples, 5970 appeared differentially expressed, at an F-test FDR cut-off of 0.01 and a 
minimum log2-fold change in expression of 1 between any of the LGm groups 1,2,4,5 and 6, and the 
least malignant glioma group LGm3.  
Among these genes, there were 183 established cancer driver genes, identified by comparison with 
the database from The Cancer Gene Census project (Forbes et al., 2015; Futreal et al., 2004), which 
is a curated database that stores information about genes frequently mutated in cancer shown 
experimentally to play active roles in disease progression. Among these are ERBB2, EGFR, CDKN2C, 
MDM2 and TET1 oncogenes, whose implication in glioma development has been thoroughly shown 
(Brennan et al., 2013; Suzuki et al., 2015).  
Apart from the core spliceosome components that are required to carry out the splice site 
recognition and subsequent catalysis, there are trans-acting splicing factors that assist in the 
selection of particular splice sites according to the cell type or extracellular signals received at a 
particular time. Comparing the list of differentially expressed genes between DNA-methylation 
subtypes with a list of RNA-binding proteins (RBPs) and splicing factors obtained from (Sebestyén, 
Singh, et al., 2015), 195 RBPs and 41 splicing factors (Figure 3.13) were found. At the top of the list 
were IGF2BP2 and IGF2BP3, insulin-like growth factor 2 mRNA-binding proteins 2 and 3, which are 
cancer and type II diabetes risk factors (Schaeffer et al., 2010; Zhang, Chan, Peng, & Tan, 1999). Their 
better characterized function involves binding to the insulin-like growth factor 2 and the cell 
adhesion protein CD44 UTRs in order to regulate transcript stability and translation (Nielsen et al., 
1999) but they have also been implicated in splicing (Cleynen et al., 2007). These two splicing factors 
are lowly expressed exclusively in LGm2 and LGm3, the two IDH-mutant subtypes having higher 
levels of DNA-methylation.  
At the criteria used for differential expression classification, the only splicing factor already known to 
be implicated in glioma was A2BP1 (RBFOX1), whose downregulation in glioblastoma has been 
shown to compromise the differentiated cell state, known to be lost in cancer cells (Hu et al., 2013). 
Curiously, among the IDH-wild type samples, this transcription factor appears downregulated in 
LGm4 and LGm5 but upregulated in LGm6 samples, where almost 8 times more mRNA is expressed 
in relation to the two other groups.  
PTBP1 and PTBP2, which promote proliferation and cell migration in glioma cell lines (Cheung et al., 
2009), were nevertheless also consistently differentially expressed between LGm groups (FDR < 4.3 x 
10-40 and 2.7 x 10-28), although having fold changes lower than 2 in relation to the LGm3 subtype. 
Interestingly, while PTBP1 was upregulated in LGm4, LGm5 and LGm1, PTBP2 was downregulated in 
LGm4 and LGm5, while keeping the upregulation in LGm1, always in relation to LGm3.  
From observation of Figure 3.13, other patterns of expression of splicing factors between LGm 
groups can be found, with PCBP3 exhibiting a descending expression gradient according to the order 
LGm3, 2, 1, 6, 5, 4. A similar trend happened with PABPC5. Another interesting pattern of expression 
across groups is the one of KHDRBS2, which shows very low levels of expression for LGm4 and 5 
subtypes and higher for the two IDH-mutant subtypes without 1p-19q codeletion LGm1 and 2. 
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Importantly, 13 of the differentially expressed splicing factors have known RNA-binding motifs and 
are thus good candidates for alternative splicing regulation through direct interaction with splicing 
enhancer and silencer sequences.  
 
  
Figure 3.13 - Differential expression statistics and relative expression levels of known splicing factor genes across glioma 
DNA-methylation subtypes. Genes that code for proteins with known RNA-binding motifs are shown in bold. 
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3.1.6 Analysis of differential splicing across DNA-methylation cluster subtypes 
In order to determine which AS events appear differentially spliced between the DNA-methylation 
cluster subtypes, a Kruskal-Wallis test was run on the PSIs of the 17097 events having variance 
different from zero, across the six LGm groups of samples. This analysis rendered a total of 10507 AS 
events showing differential splicing in at least one of the DNA-methylation cluster subtypes at an 
FDR < 0.01. This is a quite high number of significant hits, and may result from the limitations of a 
non-parametric test to deal with highly heterogeneous PSI variances shown by the different LGm 
groups. In order to check if the use of a significance value of 0.01 is indeed a good choice, six events 
were chosen from the top and bottom of the Kruskal-Wallis FDR-ranked list and their PSI 
distributions plotted (Figure 3.14). 
Figure 3.14 – PSI distributions for 12 alternative splicing events that appear differentially expressed across DNA-methylation 
subtypes, at a Kruskal-Wallis FDR significance of 0.01. The upper six plots are the top significant events (FDR < 2.0 x 10-74), 
while the bottom six are the least significant (FDR close to 0.01).  
While the first six alternative splicing events show clearly distinct PSI distributions between certain 
LGm groups, the bottom six splicing events show either having largely superimposed PSI 
distributions from all groups or very narrow PSI distributions with some outliers.  
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In order to make a better selection of differentially spliced events across LGm groups, the variance 
threshold of 0.0225 used before in the exploratory analysis was employed again. Using this event 
filter, it was possible to identify AS events able to distinguish DNA-methylation cluster samples at a 
Kruskal-Wallis FDR below 1 x 10-9 (Figure 3.15), even though large superposition of individual LGm 
PSI distributions was still observed.  
 
Figure 3.15 – PSI distributions of six AS events that just the criteria to be considered differentially spliced between glioma 
DNA-methylation clusters. Events were chosen from the 20 having the highest FDR in the group of 721 having PSI variance 
higher than 0.0225 and Kruskal-Wallis FDR below 1 x 10-9. Colours are as defined in Figure 3.14. 
To evaluate the criteria used to consider an event to be differentially spliced, a nearest shrunken 
centroid method, PAM (Tibshirani et al., 2002), was used to create a DNA-methylation classifier from 
the glioma PSI data. The idea behind using this supervised classification algorithm was to compare 
the variance and Kruskal-Wallis FDR ranges of the alternative splicing events selected for LGm class 
distinction with those previously chosen as thresholds for differential splicing across LGm subtypes. 
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A first classifier built to distinguish all six DNA methylation subtypes was created, getting an overall 
cross-validation error rate of 0.34 and yielding 2347 classifying AS events. Consistently with the high 
error rate and what had been noticed earlier by PCA, its cross-validation class prediction plot 
showed the impossibility to accurately identify samples from DNA-methylation clusters LGm1 and 
LGm6 based on PSIs (Figure 3.16A). A classifier excluding samples from these subtypes performed 
better in cross-validation, exhibiting a test error of 0.26, using 1397 AS events (Figure 3.16B). 
Figure 3.16 – Plots for cross-validation of two supervised classifiers produced with PAM algorithm, one for the six LGm1-6 
subtypes (A) and another for subtypes LGm2-5 (B). Cross-validation probabilities refer to class predictions applied each of 
the training sets. Both classifiers perform better for LGm2, LGm3 and Lgm5 subtypes. 
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Although 90% of the PAM classifier events meet the empirically chosen Kruskal-Wallis FDR cut-off of 
1x10-9, much less consensus between variance ranges was found. Indeed, the use of a minimum 
variance threshold of 0.0225 would have kept more than 70 % of the PAM classifier alternative 
splicing events from being considered differentially spliced across DNA-methylation subtypes (Figure 
3.17).  
These observations allowed to conclude that the criterion of choosing a minimum variance threshold 
for differential splicing classification across DNA-methylation groups had limitations. An alternative 
criterion for the definition of differential splicing was used instead, which consisted of setting a 
minimum value for the difference of median PSI values between at least two LGm groups. The 
minimum value was 0.1, commonly used in published studies profiling differential splicing between 
two conditions.  
A total of 1762 alternative splicing events met the criteria of having a Kruskal-Wallis FDR below 1 x 
10-9 and a minimum 0.1 median difference between two LGm groups. Remarkably, from these 
events, 1395 happened in a group of 1058 genes that are not differentially expressed among the 
same six glioma subtypes. This observation, together with the finding that most alternative splicing 
events lowly correlate with the expression of their cognate gene, provide a clear indication that 
there is a large group of alternative splicing events that are being regulated independently from 
rates of RNA polymerase II transcription, the main known mechanism dictating dependence of 
splicing rates on transcriptional output.   
Similar to what had been done with gene expression data, an identification of the number of 
differentially spliced events among glioma methylation subtypes affecting known oncogenes or 
tumour suppressor genes was made, using information from The cancer Gene Census project 
database. This comparison allowed to detect 105 differentially spliced events (corresponding to 73 
genes), from which 89 corresponded to transcripts from 64 genes that are not differentially 
expressed across DNA-methylation subtypes (see Table 3.1 for a detailed summary of this 
information).  
 
 
Figure 3.17 - Variance and Kruskal Wallis FDR of alternative splicing events that vary across DNA-methylation clusters. (A) 
Scatter plot relative to alternative splicing events considered differentially spliced according to variance and Kruskal Wallis 
FDR thresholds found adequate through visual exploration of events PSI distributions (FDR<1x10-9 and variance >0.0225). 
(B) Scatter plot relative to alternative splicing events considered to accurately distinguish DNA methylation clusters via PAM 
closest shrunken centroid classifier. 
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Table 3.1 – Number and role in cancer of genes and AS events differentially expressed across glioma DNA-methylation 
subtypes. 
 Role in Cancer 
Feature 
Type 
unknown 
causality 
in cancer 
implication 
in cancer 
unkown 
oncogene oncogene/TSG* TSG* 
DGE 5787 126 35 8 14 
DAS 1657 78 6 2 19 
DASnotDGE 969 50 4 1 9 
* TSG – tumor suppressor gene 
Particularly, in what concerns alterations in splicing factors, whereas among the list of genes 
considered to be differentially expressed these were 41, among the differentially spliced genes there 
were 46 splicing factors were found to be differentially spliced but none of these was among the 41 
differentially expressed ones. Four of the differentially spliced splicing factors are also known to 
carry cancer driver mutations: HNRNPA2B1, U2AF1, RBM10, FUS. The first two were significant 
through the-Kruskal-Wallis test and their PSI distributions are shown in Figure 3.18. The alternative 
splicing event involving HNRNPA2B1 gene was an exon whose skipping generates a protein isoform 
known as hnRNPA2, lacking residues 3 to 14 at the its beginning, which encode a nuclear localization 
signal (information source: Uniprot database). Interestingly, this protein has apart from its splicing 
function been shown to shuttle actively between the nucleus and the cytoplasm to transport mRNAs 
to particular cell sites, being particularly important in oligodendrocytes (Munro et al., 1999). Its 
prevalent localization in the cytoplasm has also been shown to be an early lung cancer biomarker 
(Nichols et al., 2000). The inclusion of the also differentially spliced exon 3 of U2AF1 causes a change 
of seven aminoacids in the protein’s N-terminal portion that allows heterodimerization with U2AF2 
to assist the function of 3’ splice site selection. This isoform, also termed U2AF35b, was reported to 
make this interaction less efficiently (Pacheco et al., 2004), with potential consequences for splicing 
regulation. Association of U2AF1 with cancer comes from studies where mutated forms of this 
protein in acute myeloid leukaemia were shown to cause abnormal splicing in cell-cycle regulator 
genes and RNA processing genes mutated in different cancers (Przychodzen et al., 2013). 
Another two of the most differentially spliced events across LGm groups affecting splicing factor 
genes involved PCBP2 and HNRNPD. Both events (Figure 3.18) involve the generation of alternative 
protein isoforms of these Poly(rC)-binding protein and hnRNP family protein whose specific 
functions are not known. PCBP2 is involved in the control of innate immune response (You et al., 
2009) and hnRNPD (Yoon et al., 2014) in increasing or decreasing the steady state of mRNA 
molecules, with important implications in genome integrity maintenance. 
Many of the alternative splicing events found in the literature to be relevant in glioma were found to 
be differentially spliced in this study, confirming their general interest in the context of the disease, 
namely in differentiating between glioma subtypes. One such example is RTN4 exon 3 inclusion, 
known to be regulated by the splicing factor PTBP1 and found to be preferentially included in LGm2 
and LGm3 and the least in LGm4 and LGm5. Exon 6 of ANXA7, known to be preferentially included in 
the brain, had a median PSI below 0.1 for LGm1,4,5,6. PSI medians for the mutual exclusive event 
involving TPM1 exons 5 and 6 got close to zero in LGm4,5, and higher than 0.5 in other subtypes. 
FGFR1 exon 3 was preferentially excluded in LGm4,5, with the resulting predicted increase of FGFR1 
signalling. EGFR, in turn, exhibited the highest expression in LGm4 and the least in LGm6, but no 
differential splicing was found related to it. Finally, exon 8 of the tumour suppressor gene RECK was 
specifically excluded in LGm4.  
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Figure 3.18 – PSI distributions of four alternative splicing events that affect splicing factor genes. Colours are according to 
DNA-methylation subtypes. 
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3.1.7 Functional Analysis of gene expression and alternative splicing changes in LGm subtypes 
In order to identify biological processes enriched among differentially regulated alternative splicing 
events, GSEA was done for Reactome and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways, as well as Biological Process (BP) gene ontology (GO) terms-analysis. This analysis 
returned very interesting information to assist in the study of splicing changes in glioma. In parallel, 
a similar analysis was run for the differential gene expression data. Gene sets found enriched at an 
FDR adjusted p-value cut-off of 0.05 were considered. Significantly, no overlap was found between 
the sets enriched in differentially expressed and differentially spliced genes (Figure 3.19-3.20). 
Cell pathways and biological processes enriched among differentially expressed genes involved cell 
adhesion, immune response, p53-signalling pathway and pathways affecting certain cancer types.  
As for alternative splicing, there were fewer gene sets returning statistically significance. While no 
cancer-specific pathways appeared affected, some neuronal pathways did. 
KEGG pathways, GO BP terms and Reactome pathways associated with RNA processing and 
specifically the spliceosome were enriched in differentially expressed genes, consistently with what 
had already been reported for colon adenocarcinoma and breast cancer (Danan-Gotthold et al., 
2015). Genes having their transcripts ratios affected include many encoding ribosomal proteins (e.g. 
RPL10, RPS15, RPL38, RPL13A, RPSA, RPS15A), genes related to nonsense mediated mRNA decay 
(e.g. SMG7) or YWHAZ that encodes the 14-3-3 protein zeta/delta, a protein implicated in many 
signal transduction pathways and having known roles in mediating apoptotic pathways (Nishimura et 
al., 2013). 
Among the enriched Reactome pathways, there were two related with protein metabolism 
regulation (involving genes like TUBA1B, RPL7, TUBA1C, EEF1B2, EEF1G), signal recognition particle 
(SRP) dependent targeting of membrane and secretory proteins to the cell membrane, involving 
again ribosomal genes like SEC11A, RPN2, SSR2. Interestingly, genes coding for apoptotic proteins 
was one, (like CTNNB1, TJP2, MAPT, ACIN1, DFFA) are also enriched among those having splicing 
changes across DNA-methylation glioma subtypes. KEGG mitochondrial pathways were found 
enriched among genes with altered splicing across gliomas. So were Parkinson’s disease gene sets 
that include NDUFV3, PARK7, ATP5J, which code for nicotinamide adenine dinucleotide (NAD) and 
adenosine triphosphate (ATP) conjugated proteins. Most of the genes in this set ranking high for 
differential splicing were also differentially expressed though. As for alterations in Alzheimer’s 
disease associated genes, those contributing the most to the enrichment score are shared with the 
Parkinson’s enriched gene set. So are BID, APP (the amyloid beta precursor protein, which appears 
to be specifically affected at the level of its alternative splicing and not in terms of overall gene 
expression), protein phosphatases PPP3CA/C genes or the important proliferation/cell-
differentiation signal-transduction mediator MAP3K. As for the pathogenic Eschericia coli infection 
pathway hit, the genes that contributed to the enrichment score had many different functions. They 
could be 1) cytoskeleton associated proteins genes, like TUBA1B/C, TUBB6/3 that are brain-specific 
tubulin variants, and actin-related ACTB, ACTG1, ARPC4 genes, 2) genes associated with cell-
adhesion functions (e.g. CTNNB1, ITGB1), 3) signalling transduction (e.g. YWHAZ, FYN1, ARHGEF2) 
and finally, 4) a very important cell-cycle regulator encoding gene: CDC42. Still about this gene set, 
the gene classes that appeared to be exclusively affected at the level of alternative splicing were the 
actin related and signalling ones. 
48 
 
 
 
 
Figure 3.19 – Biological pathways and cellular processes enriched among differentially spliced and differentially expressed 
genes. Significant KEGG pathways and GO Biological Process terms obtained by GSEA for alternative splicing (AS) and gene 
expression (GE) are shown. 
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Figure 3.20 – Biological pathways and cellular processes enriched among differentially spliced and differentially expressed 
genes. Significant Reactome pathways obtained by GSEA for alternative splicing (AS) and gene expression (GE) are shown. 
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3.2 INVESTIGATION OF THE VALUE OF ALTERNATIVE SPLICING IN GLIOMA PROGNOSIS 
Various factors act together in determining disease progression. In the case of glioma, tumour grade, 
age of the patient and LGm subtype, a molecular classifier that incorporates the information of other 
molecular risk factors that have been known for some time: IDH mutation status and 1p19q 
chromosome arms deletions, are the most important factors to predict patient outcome. 
The LGm classification system is quite recent and much is still to be discovered in terms of the 
specificities of these subtypes, namely in terms of regulation of alternative splicing. Discovery of 
LGm subtype markers that impact more on the disease, or that can at least be useful for diagnosis, 
for example in the absence of DNA-methylation data, can be quite important. 
Furthermore, alternative splicing regulation could still be informative in terms of prognosis beyond 
the known risk factors. Using the follow-up information from the patients of the studied cohort, in 
particular the overall survival, the prognostic value of alternative splicing was studied.   
3.2.1 Prognostic value of gene expression and alternative splicing malignancy axes 
Gene expression and alternative splicing organized patients very similarly along the main principal 
component of explained variance that grouped the samples consentaneously with clinical indicators 
and established/published molecular signatures. In particular, these principal components organized 
the samples along a gradient of malignancy, which separated better grade 4 from grade 2 samples, 
as opposed to grade 3 samples that localized mostly in between.  
Glioma histological grade dictates very different prognosis, as can be observed in Figure 3.21.  
Figure 3.21 – Survival curves for different WHO grade gliomas. . Kaplan-Meier curves for grade IV GBM patients, and grades 
II (LGG2) and III (LGG3) patients, show three clearly distinct prognosis groups.  
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It then became interesting to test if the principal component 2 of the whole alternative splicing data, 
as well as the gene expression principal component 1, could indeed reflect a gradient of malignancy, 
even better than WHO grade classification in predicting patient outcome. Cox proportional-hazards 
models were run both on the sample scores of the referred principal components and on the 
samples’ WHO grade strata, using overall survival as the event of interest. The general equation for 
performing the regression was: 
h(t) = h0(t) exp(βx1 x x1 ), 
 
where h0(t) is the baseline hazard at time t, βx1 and x1 are respectively the regression coefficient and 
values taken by the independent explanatory variable x1 (“Fundamentals of Biostatistics 7th edition 
(9780538733496) - Textbooks.com,” 2016)(see Methods).  
Then, the amount of information about patient’s survival taken from the model was assessed using 
the concordance index, an indicator that is part of the output from the coxph.fit function from the 
Bioconductor package prodlim, and consists on a goodness-of-fit test that compares the ranks of the 
survival time of the patients with the ones predicted by the explanatory variable being evaluated 
(Harrell, Califf, Pryor, Lee, & Rosati, 1982). The results are presented in Table 3.2. Cox proportional-
hazards model for alternative splicing data PC2 got a higher concordance index than the Cox model 
based exclusively on WHO grade, as much as gene expression PC1 did, which showed the value of 
transcriptional programs associated with these components of variance to predict patient outcome 
in a finer way than tumour grade does. 
Table 3.2  – Cox proportional-hazards models for malignancy-reflecting variables. Hazard Ratio (HR) with 95 % confidence 
interval (95 % CI) for patient overall survival according to different factors. Number of events: 239 out of 659 patients. p-
values shown are for the log-rank test and relative to the HR estimate of each variable, being all significantly against the 
null hypothesis of the variable not having an effect on survival (α = 0.001). HR – Hazards Ratio; CI – Confidence interval. 
Variable Levels HR 95 % CI p-value  Concordance index  
Alternative 
Splicing PC2 
Sample 
score 
1.19 x 1017 9.15 x 1014-1.54 
x 1019 
< 0.001  0.80 
Gene 
Expression 
Splicing PC1 
Sample 
score 
0.133 0.104-0.17 < 0.001  0.81 
WHO Grade III 3.21 2.15-4.78 < 0.001  0.78 
 IV 19.8 12.9-30.3 < 0.001   
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3.2.2 Prognostic value of individual genes and AS events  
With the aim to discover alternative splicing events and genes that could work as good glioma 
prognostic markers, Cox proportional-hazards models were run for each alternative splicing event 
and gene. In addition, since there was the interest to distinguish the relative strength of splicing 
events in predicting patient’s overall survival as compared to the expression of their cognate gene 
alone, so as to get insight into the clinical relevance of particular regulated exons, additive Cox 
regression models taking into account gene and alternative splicing event as explanatory variables 
were also run (see Methods).  
At a level of significance of 0.01 FDR, a very high number of genes and alternative splicing events 
were found to be informative about patient’s overall survival: 11794 out of the 15189 genes, 6657 
out of 17097 alternative splicing events (2011 affecting 1204 genes that are not themselves 
prognostic markers) and 5991 alternative splicing events in the group of models adjusted for gene 
expression levels (1767 affecting 1072 genes that are not themselves prognostic markers). 
Distributions of concordance indexes for the statistically significant markers from this survival 
analysis are shown in Figure 3.22, in which it becomes clear that there are potentially good 
individual markers among both alternative splicing events and expressed genes, showing 
concordance indexes above 0.6. Although this value is lower than the ones found previously while 
testing for the prognostic value of the principal components, it still tells about the potential of these 
individual transcript as malignancy markers. Effectively, the presence of high numbers of 
“expressionally prognostic genes” in glioma in comparison to other types of tumour had been 
previously reported in a pan-glioma study on cancer prognostic genes from RNA-seq data (Anaya, 
Reon, Chen, Bekiranov, & Dutta, 2016). In this study, it is pointed out that parameters like cohort 
size and number of events (deaths) do not explain the different numbers of prognostic marker genes 
found for different cancers, and rather three other possible tumour specific parameters for these 
differences are suggested: intra-disease heterogeneity or responses to treatment that may act as 
putative confounders in the Cox model, and the possibility of differing levels of transcriptional 
dysregulation is also referred.   
Distribution of concordance indexes of Cox hazards-models for individual genes and alternative 
splicing events. GE – gene expression; AS – alternative splicing; C-Index – Concordance index. 
We decided to further test if any of the alternative splicing events or expressed genes could add 
predictive power to the information already brought-in from DNA-methylation cluster, grade and 
age, as published in (Ceccarelli et al., 2016). This multivariate model was indeed confirmed to 
perform the best in the RNA-seq cohort used in the present study (in the published work, clinical 
Figure 3.22 – Distribution of concordance indexes of Cox hazards-models for individual genes and alternative splicing events 
with prognostic value at Cox adjusted p-value below 0.01.  GE – gene expression; AS – alternative splicing; C-Index – 
Concordance index. 
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cases studied included both microarray and RNA-seq transcriptomic samples), presenting a 
concordance index of 0.867 (Figure S4). Then, multivariate Cox regression models were rerun for all 
genes and alternative splicing events, adjusting for DNA-methylation cluster, grade and age. 
Alternative splicing event models were also adjusted for the respective cognate gene expression, so 
as to be able to identify events with prognostic value independent of that of their cognate genes’ 
overall transcript abundance. 
From this analysis, at an FDR cut-off of 0.01, there were two alternative exons with prognostic value 
(Table 3.4): exon 2 of the NLGN4X gene, that codes for a neuroligin family protein, responsible for 
neuronal synapse remodelling, and exon 3 of gene PDGFRA, one of the RTKs that appears amplified 
in glioma at higher frequencies (2-4 %). However, these alternative splicing events had extremely 
low PSI variances to be considered regulated events (variances below 1 x 10-4), with the NLGN4X- 
involving event having a hazardous effect with a mean PSI value of 0.0005 and zero interquartile 
range, and the PDGFRA-involving event being protective but with mean PSI value of 0.9968 and 
interquartile range of 0.0028. For this reason, they were considered not to have any biological 
interest and to be too difficult to use as prognostic markers. As for the equivalent Cox regression 
models for gene expression, at an FDR cut-off of 0.05 there was one gene that appeared to add 
prognostic value in glioma: C1orf51 or CIART, a gene involved in circadian rhythm regulation in the 
mouse liver (Annayev et al., 2014) and the human prefrontal cortex (Chen et al., 2016). This gene 
showed a protective effect (HR 0.62) (Table 7).  
Because the grade IV glioblastoma multiforme samples have markedly distinct gene expression and 
are suggested by PCA plots to be more homogeneous in relation to grades 2 and 3 ones, one could 
consider that some LGG-exclusive clinically relevant gene expression and splicing alterations failed to 
be detected in Cox models including the whole glioma cohort. Cox regression models for gene 
expression and alternative splicing, with adjustment for DNA-methylation cluster, grade and age 
were thus run again only with grades II and III patients, in order to detect yet some additional 
prognostic markers. At a 0.05 FDR threshold, two genes were detected: C1orf51 and TGIF1, the latter 
a conserved transcription regulator that belongs to the TGFβ pathway (Table 3.3). As for the Cox 
models including alternative splicing events, there were eight events found to significantly improve 
performance (Table 3.3). Apart from exon 4 of gene NHSL1, whose PSI variance was of 0.015, all the 
others had again too low variances (below 1 x 10-4) to be considered interesting as prognostic 
markers. NHSL1 is a gene with unknown function and actually the one whose model produced the 
best concordance index (Table 3.3). 
Table 3.3 – Cox proportional hazards models for prognostic maker genes, after adjustment for DNA-methylation cluster, 
grade and age. Number of events: 207 out of 627 patients. p-values shown are for the log-rank test and relative to the HR 
estimate of each variable, being all significantly against the null hypothesis of the variable not having an effect on survival 
(α = 0.001). HR – Hazards Ratio; GE – gene expression. 
Model Variable HR FDR Concordance index  
pan-Glioma: GE level + DNA-
methylation cluster + Grade 
+ Age 
C1orf51 0.62 < 0.05 0.876 
LGG: GE level + DNA-
methylation cluster + Grade 
+ Age 
C1orf51 0.50 < 0.05 0.859 
LGG: GE level + DNA-
methylation cluster + Grade 
+ Age 
TGIF1 1.98 < 0.05 0.858 
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The number of prognostic markers found in this analysis was quite reduced, even after increasing 
the FDR cut-off for the Cox regression coefficient estimate from 0.01 to 0.05. Therefore, it may be 
concluded that alternative splicing and gene expression individual markers do not add further 
prognostic information for stratification of glioma patients. 
 
 
 
Table 3.4 – Cox proportional hazards models for prognostic maker alternative splicing events, after adjustment for gene 
expression, DNA-methylation cluster, grade and age. Number of events: 207 out of 627 patients. p-values shown are for 
the log-rank test and relative to the HR estimate of each variable, being all significantly against the null hypothesis of the 
variable not having an effect on survival (α = 0.001). HR – Hazards Ratio; GE – gene expression; AS – alternative splicing. 
Model Variable HR FDR Concordance index  
pan-Glioma: PSI + GE level + 
DNA-methylation cluster + 
Grade + Age 
NLGN4X 2.8x1029 < 0.01 0.871 
pan-Glioma: PSI + GE level + 
DNA-methylation cluster + 
Grade + Age 
PDGFRA 1.0x10-9 < 0.01 0.875 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
CACHD1 0.00 < 0.05 0.836 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
FZD6 0.00 < 0.05 0.834 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
MEST Inf < 0.05 0.840 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
NLGN4X 7.0x1033 < 0.05 0.847 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
NHSL1 1.1x10-2 < 0.05 0.852 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
HKR1 7.9x104 < 0.05 0.845 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
RBM42 1.3x10-218 < 0.05 0.845 
LGG: PSI + GE level + DNA-
methylation cluster + Grade 
+ Age 
IMMT 1.85x1045 < 0.05 0.844 
 
Next, we enquired about the existence of interesting, alternative splicing related, prognostic markers 
associated with the very important histological parameters tumour grade and molecular parameter 
DNA-methylation cluster. In particular, it was reasoned that prognostic markers associated with 
grade, independently of DNA-methylation cluster and age, and therefore with tumour progression, 
would be statistically significant variables in the models adjusted for DNA-methylation cluster and 
age. Similarly, and more interestingly, it was also thought that prognostic markers associated with 
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DNA-methylation cluster, independently of grade and age, would be statistically significant variables 
in models adjusted for grade and age. 
New series of multivariate Cox proportional-hazards models were run for gene expression and PSI 
levels, in combination with, on the one hand, grade and age, and on the other, DNA-methylation 
cluster and age, whose results in terms of predictive value are shown in Figure 3.23A. At an FDR cut-
off of 0.01, there were 3969 genes that produced improved Cox models in relation to grade and 
3727 after further adjustment for age at diagnosis. At the same cut-off, there were 346 alternative 
splicing events adding prognostic value to the model adjusted for grade and 237 to the model 
adjusted for both grade and age (apart from the cognate gene expression adjustment). These 
affected 209 genes, 75 of which were not prognostic markers in terms of gene expression. These 
gene- and splicing event-including models have concordance indexes still below 0.867, the maximum 
for this cohort (see above), with the exception of models for genes TGIF1, EMP3, TNFRSF12A and 
TIMP1, and six including both expression and alternative splicing involving genes BID, TNFRSF12A, 
PSTPIP1, TNK2, POLL. In the latter though, alternative splicing events had non-significant Cox hazard 
ratio estimates at FDR 0.01 or 0.05. Nevertheless, the 237 alternative splicing events and 3727 genes 
appeared as a quite interesting set of prognostic markers to be analysed, namely by their putative 
association with particular LGm DNA-methylation clusters.  
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Figure 3.23 – Distribution of concordance indexes of Cox proportional-hazards models for individual genes and alternative 
splicing events with prognostic value at Cox adjusted p-value below 0.01. (A) Models adjusted for Age and/or Grade; (B) 
Models adjusted for Age and/or DNA methylation subtype GE – gene expression; AS – alternative splicing; C-Index – 
Concordance index; DNAmet - DNA methylation subtype.   
Finally, as an attempt to discover additional prognostic alternative splicing events after adjustment 
for grade, age and gene expression, Cox regression models run only for the LGG cohort were 
generated. This resulted in the discovery of 675 events at an FDR cut-off of 0.01, affecting 557 genes, 
244 of which were not prognostic markers. The 493 novel prognostic alternative splicing events 
detected in the LGG cohort were also gathered for analysis of association with the LGm groups.  
There were 553 genes that produced improved Cox models in relation to DNA-methylation cluster 
and 130 after further adjustment for age at diagnosis (Figure 3.23B). Models including alternative 
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splicing yielded 63 events adding prognostic value (FDR < 0.01), after adjusting for DNA-methylation 
cluster, and, after adjusting for both DNA-methylation cluster and age, the same two previously 
found for the models including grade (Table 3.4). The fact that the same alternative splicing 
prognostic markers were found for Cox models that included or excluded adjustment for grade 
suggests that alternative splicing regulation does not contribute, at least in great extent and in a way 
that is independent from gene expression, to grade-associated glioma prognosis prediction after 
adjustment for DNA-methylation cluster. Still, it should be added that, in the models that include 
DNA-methylation and age but not grade, if an FDR cut-off of 0.05 is in turn used, there are additional 
39 alternative splicing events that become significant contributors to the multivariate Cox model, 
which may still be looked-upon as good candidates to be grade and thus malignancy degree-
associated markers in glioma. Statistics for the Cox regression models including these 41 alternative 
splicing events are presented in Table S2.    
In order to focus on alternative splicing related prognostic markers potentially associated with 
glioma DNA-methylation cluster, only the genes and alternative splicing events that showed to be 
able to add prognostic value to glioma patient overall survival prediction in addition to grade and 
age will be considered from this point on.  
3.2.3 Identification of potential trans-acting regulators of splicing in different DNA-methylation 
subtypes 
In order to discover likely mechanisms of regulation in trans of alternative splicing in glioma DNA-
methylation subtypes, genes coding for RNA-binding proteins (RBPs) and splicing factors (SFs), 
namely RNA-binding ones, were identified among prognostic markers and differentially expressed 
genes described in the previous sections.  
Among the 3727 good prognostic gene markers after adjustment for grade and age, there were 328 
RNA-binding proteins and 75 splicing factors from the list taken from (Sebestyén, Singh, et al., 2015). 
From these, 106 RBPs and 20 SFs were differentially expressed across DNA-methylation clusters, at 
FDR < 001 and fold change > 2 (Figure 3.24A). 
Focusing on SFs with a known RNA-binding motif would enable an in silico search for their putative 
pre-mRNA targets. 17 RBP and SF prognostic markers had known RNA-binding motifs, six among the 
differentially expressed across DNA-methylation subtypes: IGF2BP2, IGF2BP3, KHDRBS2, PCBP3, 
RBM47 and RBMS1 (Figure 3.24B). These RBPs were thus selected for further investigation on the 
mechanisms of alternative splicing regulation in glioma. 
 
58 
 
Figure 3.24 – Prognostic splicing factors associated with LGm subtype. Numbers are relative to genes whose predicting 
adjusted p-values in multivariate Cox regression models adjusted for tumour grade and patient age at diagnosis were below 
0.01, except for the DGE sets, which refer to differentially expressed splicing factor genes across LGm subtypes. (A) Venn 
diagram for splicing factor genes (SFs); (B) Venn diagram for splicing factor genes coding for proteins with known RNA-
binding motif. 
Before moving into the next section, a note may be left about other promising RNA-binding splicing 
factors that will not be included in the study of regulation of splicing in trans but that are still 
promising alternative splicing regulators for having a relevant function in glioma. Splicing factors like 
A2BP1 (or RBFOX1), PABPC5, RBM24, RBM42, YBX1, CELF4 and CELF5, although having been found 
to work as good glioma prognostic markers, ceased to contribute to prognosis prediction when 
glioma grade and patient’s age were accounted for. On the other hand, genes like PABC1, 
HNRNPA1L2, TUT1, HNRNPA1, FXR2 and KHDRBS3, which still added prognostic value to Cox 
regression models with grade and age adjustments, did not meet the cut-off value of fold changes 
between at least two DNA-methylation groups to be included in the group of differentially expressed 
genes. Still these SFs had log2-fold change differences of around 0.9 between at least one pair of 
LGm subtypes. Because the search for mechanisms of splicing regulation relied on the detection of 
splice ratio switches between groups of samples that also differed in their expression of each 
candidate splicing regulator, it seems important to guarantee that the magnitude of these 
expression changes is high enough. 
3.2.4 Identification of DNA-methylation subtype associated prognostic alternative splicing events 
From the 237 alternative splicing event prognostic markers identified, 122 were in fact differentially 
spliced between DNA methylation subtypes at the criteria described in section 3.1.6. From the 675 
identified after survival analysis performed only on the LGG cohort, an additional 215 appeared 
differentially expressed (Figure 3.25).  
From these 337 events with significant prognostic value and differentially spliced across LGm 
subtypes, 45 were on 40 differentially expressed genes (FDR < 001 and log2 fold-change > 1) (Figure 
3.25B). There were 246 alternative splicing events showing statistically significant correlation with 
their gene expression, affecting a total of 208 genes. Although these alternative splicing events 
might be affected by one of the putative RBPs specific of DNA-methylation clusters, this other 
dependence on own gene expression might interfere with the detection of such regulatory function. 
In addition, 221 (affecting 193 genes) out of the 337 AS events of interest already corresponded to 
genes detected as prognostic markers. There were 50 events that appeared as gene-expression 
independent prognostic markers (Figure 3.25), mostly skipped exons and alternative-first exons. 
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Figure 3.25 - Relations between alternative splicing prognostic markers and alternatively spliced and differentially 
expressed genes. (A) Venn diagram for the intersection of different sets of alternative splicing events with predictive 
adjusted p-values in multivariate Cox regression models adjusted for grade (except for GBM models) and age below 0.01. 
Numbers were obtained from Cox regression models applied to all glioma (panGlioma), only low-grade-glioma (LGG) and 
only glioblastoma (GBM) samples. DAS - differentially alternatively spliced events across LGm subtypes. (B) Venn diagram 
for the intersection of different sets of alternative splicing events: affecting genes that are differentially expressed 
(ASEvents_DGE), whose PSIs correlate with the expression of cognate gene (ASEvents_GECorr), which affect genes that 
have prognostic value independent from grade and age (ASEvents_ProgGene), which have prognostic value independent 
from grade and age (ASEvents_ProgDAS). 
Finally, PCA plots for the 337 alternative splicing prognostic markers whose association with LGm 
groups was determined here are shown in Figure 3.25. These show the ability of this selected pool of 
events to perform a refined distinction between epigenetic subtypes. 
Figure 3.26 – Principal Component Analysis plots made on 337 prognostic AS events associated with LGm 
subtypes. Selected PCs are plotted. Colours are according to DNA-methylation subtype. 
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3.3 DISCOVERY OF ALTERNATIVE SPLICING REGULATION MECHANISMS IN GLIOMA 
In recent years, great advances have been made in terms of the identification of splicing regulatory 
elements and factors, among which RNA-binding proteins. To investigate alternative splicing 
regulatory mechanisms in trans in a particular tissue of a model organism or cell line, one can 
combine alternative splicing profiling in a control and loss-of-function in vivo model for a given 
splicing factor with CLIP-seq technology that will allow to identify mRNA-binding regulatory regions 
for the same splicing factor, and in turn produce a very good set of potential targets of splicing 
regulation. However, while not all RNA-binding splicing factors have been subject to this kind of 
detailed studies, in silico approaches can help generating this very same kind of hypotheses. Tools 
like the FIMO software (Grant, Bailey, & Noble, 2011) allow to, from the knowledge acquired in vitro 
about RNA-binding protein (RBP) binding preferences, map motifs along the genome and 
subsequently identify regions of higher density of motifs in the vicinity of regulated exons. 
Information taken from the application of this kind of analysis is able to compensate for the lack of 
CLIP-sequencing availability.  
From the occurrence of an RBP binding motif in intronic or exonic regions flanking a regulated exon, 
one can infer a good candidate alternative splicing regulatory region. However, it is not possible to 
guess if it will function as an enhancer (ESE/ISE) or as a silencer (ESS/ISS). But, if one considers that 
the level of expression of an RBP splicing factor will correlate with the levels of inclusion of its target 
exons, then the enhancer vs silencer nature of the RBP on those targets may be extracted from that 
correlation. Recently, the Genotype-Tissue Expression (GTEx) project made available a set of RNA-
seq data from thousands of post-mortem samples from 32 different tissues coming from healthy 
individuals (Lonsdale et al., 2013). The idea of combining the transcriptomic quantification from 
GTEx with the running of FIMO with known RBP-binding motifs, in order to build RNA binding maps 
for splicing regulators, arose in the lab. 
In this section, our attempt to implement this strategy for RBP splicing regulatory mechanism 
discovery will be described. GTEx was used as a powerful large data set coming from normal-
functioning tissues that allows the best possible outline of each RNA splicing map. The same 
approach was then applied to the TCGA data set. Specifically, a focus will be put on trying to relate 
prognostic splicing factors with prognostic alternative splicing events differentially regulated in LGm 
groups. 
3.3.1 On the likeliness of glioma prognostic alternative splicing being mediated in trans 
From the previous section, among the prognostic markers that appeared strongly associated with 
DNA-methylation subtype differences, there were 337 alternative splicing events and six RNA-
binding splicing factors with a known binding motif.  
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Figure 3.27 – Concordance between glioma TCGA and GTEx splicing factor expression to alternative splicing events PSIs 
correlations. Scatter plots of -log10(FDR) values taking positive or negative values according to the sign of the rho of 
Spearman. 
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To ascertain the odds for each of the six RBPs to have a significant role in determining alternative 
splicing regulation decisions, we inspected whether RBP expression levels concordantly (i.e. with the 
same positive or negative sign) correlated in the TCGA glioma and the GTEx cohorts. Scatter plots 
relating the adjusted p-values of tests for correlation between RBP expression and PSIs were 
produced (Figure 3.27). While for RBM47 and IGF2BP3 no trend for an agreement in sign and 
strength of correlations was detectable, this was more the case for the remaining proteins, 
especially for KHDRBS2, which encodes a protein highly expressed in the brain (data not shown). To 
have a comparison of how this same kind of plot would look like for RBPs known to have 
preponderant effects in alternative splicing regulation, PTBP1 and A2BP1 (RBFOX1) correlation test 
results were also plotted (Figure S5).  
The hypothesis that the four RBPs that showing correlation with exon inclusion ratios similar in the 
cancer and normal tissue samples in fact regulate some of the alternative splicing events of interest 
through direct binding was evaluated. 
Frequencies of binding motifs in splicing regulatory sequences were checked for, without and with 
the additional requirement of significant correlations between RBP gene expression and PSI in both 
GTEx and TCGA samples (Figure 3.28). 
Indeed, there were binding motifs for each of the RBPs in the groups of differentially spliced events 
(Figure 3.28, left panel). In addition, for all RBMS1, PCBP3, KHDRBS2 and IGF2BP2 factors, there is a 
larger proportion of events having RBP motif together with significant correlation with RBP 
expression among differentially spliced events when compared to the background of all alternative 
splicing events (Figure 3.28, right panel).  
Figure 3.28 – Evidence for alternative splicing regulation by four RBPs. Barplots show the proportions of all 17151 events 
(“All.Events”), differentially spliced events (“DAS.Events”) and differentially spliced events that have prognostic value 
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independently of tumour grade and patient’s age (“DAS_Prog.Events”) that meet two different criteria: on the left, presence 
of RBP-binding motif; on the right, presence of RBP-binding motif and correlation with RBP expression (Spearman FDR < 
0.01) in both glioma TCGA and GTEx samples. The table shows the same information in absolute frequencies. 
3.3.2 RNA splicing maps 
Here, the regulation of the most frequent event type, exon skipping, will be studied. An alternative 
exon located between two constitutive exons will be spliced as efficiently as its exon-defining 3’- and 
5’-splice sites are recognized by the spliceosome.  
In this section, we attempt to discover whether any of KHDRBS2, PCBP3, IGF2BP2 or RBMS1 proteins 
has a mode of regulation that obeys to defined spatial rules, i.e. their splicing enhancing or silencing 
roles are determined by the distance of their binding to mRNA to nearby splicing sites.  
Essentially, different combinations of thresholds of significance for, on the one hand, correlations 
between PSIs and RBP expression levels and, on the other, for FIMO p-values for each given RBP 
binding motif were used in order to find which set of these cut-off parameters maximizes the 
strength of association between RBP-expression level-dependent splicing ratios and presence of 
RBP-binding motifs. The strength of association was measured with the one-sided Fisher’s Exact test, 
taking the alternative hypothesis that there is a higher proportion of alternative splicing events 
correlated with RBP gene expression when the events’ regulatory regions are enriched for RBP 
binding motifs. Tests for positive (enhancing of exon inclusion) and negative (silencing of exon 
inclusion) correlations were made separately for each of eight regulatory regions adjacent to the 
splice sites of the implicated alternative and constitutive exons (Figure 3.29, see Methods), for each 
combination of cut-off parameters. The cut-off parameters for the two regions that returned the 
best result on the Fisher’s exact test were then used to create RNA splicing maps, which result from 
the application of the same statistical test along the 800 bp of regulatory regions defined, using a 
sliding window spanning 50bp (see Methods for a detailed explanation).  
This approach was validated using PTBP1, the ubiquitous splicing factor known to silence exon 
inclusion through binding to the intronic region that is right upstream of it and to enhance exon 
inclusion when binding the immediately downstream intronic region (Raj & Blencowe, 2015). The 
results are presented in Figure S6 and show clearly a peak of silencing regulation at around 40 bp 
upstream of the regulated exon, remarkably visible both for the GTEx normal tissue (Figure S6A) and 
the glioma TCGA (Figure S6B) datasets. In addition, the effect of silencing appears along the whole 
150 intronic region upstream from the regulated exon (region s2_I) and also in the last 50 bp of the 
same exon (region e2_E). As for the known PTBP1 enhancing effect upon binding to the downstream 
intron, this appears for one of the “GTEx” maps and also for one of the “TCGA” maps. These results 
effectively validate the power of the approach presented here for the discovery of alternative 
splicing regulation rules. The fact that results were in great part concordant for the two data sets 
indicates that, first of all and as already known from its described role in supporting glioblastoma 
progression, PTBP1 is functional in the glioma tissue and thus that this methodology can be used to 
find robust hypotheses for mechanisms of alternative splicing regulation acting in cancer tissue. The 
fact of having less significant results for the TCGA cohort relates at least in part to the fact that the 
number of alternative splicing events used to generate these maps is much lower: 4859 alternative 
splicing events as compared to 14769 from GTEx. 
Next, RNA splicing maps were generated for the other four splicing factors of interest in this glioma 
study. While using the GTEx data set to find regulatory regions for RBMS1, the most significant 
Fisher’s p-value obtained for any of the regions and threshold parameters was above 0.01,quite high 
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in comparison to what was obtained for the other genes. So, the analysis of RBMS1 alternative 
splicing regulatory role was dropped at this point. It is possible that this protein’s role on alternative 
splicing does not follow this direct mode of regulation.  
As for PCBP3, it is expressed at higher levels in the brain, the cerebellum, the pituitary and the testis 
(data not shown) and its expression has been shown to be particular of post-mitotic, differentiated 
cells, similarly to what happens with A2BP1. It showed as most promising alternative splicing 
regulatory regions the intronic mRNA segment that is located upstream from the second constitutive 
exon (s3_I) and the intronic region that follows the alternative exon (e2_I) (Figure 3.29). In both 
cases, the result of the Fisher’s test were significant for enrichment of binding motifs in events that 
correlate negatively with PCBP3 expression. When plotting RNA maps using the FIMO and 
correlation FDR cut-offs that returned these stronger enrichments, two peaks representing PCBP3 
binding regions resulting in alternative exon silencing were commonly observed in the two maps. 
However, there were also peaks that were different, namely the enhancing region at around 
position 50 of region s2_I and the silencer region just before the start position of the second 
constitutive exon in region s3_I. It is possible that PCBP3 has a role in favouring exon skipping in 
events whose regions e2_I have very high affinity binding motifs (corresponding to 3.83 FIMO p-
value threshold of the second map) and either an alternative exon splicing role or exon skipping for 
event whose regions s2_I or s3_I have lower affinity binding motifs (corresponding to the less 
stringent 3.05 FIMO p-value threshold of the first map).   
RNA splicing maps for PCBP3 using the TCGA dataset looked unrelated with the ones previously seen 
for the GTEx dataset, whatever the FIMO p-value thresholds used. Regions where there was a higher 
enrichment of PSI to PCBP3 expression correlation upon putative binding of PCBP3 were exonic 
regions e2_E and e1_E, which indeed presented enhancing peaks in each of the two PCBP3 splicing 
maps. It remains to be ascertained if in glioma, changes in factors other than PCBP3 expression, like 
PCBP3 protein turnover or activity, or else alterations in its protein interactors, might be causing 
these different responses to PCBP3 transcriptional output.   
Because PCBP3 presented very strong correlations between its expression and a relatively (in 
comparison with KHDRBS2, PTBP1 or A2BP1) low number of alternative splicing events, both in the 
GTEx and the TCGA cohorts, it may be responsible for the regulation of a minority of alternative 
splicing events due to the requirement for stronger binding affinity. This would favour the e2_I map 
of GTEx as the most reliable (the second map in Figure 3.29A), whose best parameters for a splicing 
RNA-binding plot actually were the same as for the ones of another region: the end of the first 
constitutive exon. 
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Figure 3.29 – PCBP3 RNA-binding maps for the general exon-skipping (SE) alternative splicing event. (A) Two RNA-binding 
maps produced using the GTEx multi-tissue dataset. (B) Two RNA-binding maps produced using the glioma TCGA dataset. 
RNA-binding maps shown were generated using correlation FDR threshold and FIMO p-value as shown on the bottom and 
the right side of the heat maps, respectively. Distance in base pairs (bp) relative to the closest splice site is shown. Different 
names for the eight intronic (150 nucleotides long) and exonic (50 nucleotides long) regulatory regions defined are indicated 
in grey. Constitutive exons are shown in black and alternative exon is shown in white. Corr-type – Correlation type: blue for 
enhancement and red for silencing of exon inclusion. 
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KHDRBS2 is expressed mostly in the brain, thyroid, lung, pituitary, intestine and spleen (data not 
shown). It was the splicing factor that showed the highest proportion of alternative splicing events 
having concordant correlation test results for RBP expression vs events PSIs between the GTEx and 
the TCGA datasets (Figure 3.30).  
RNA splicing maps for the GTEx datasets presented a peak of silencing activity for KHDRBS2 in the 50 
bp of intronic region that precedes the alternative exon (Figure 3.30). This peak exhibited robustness 
to varying combinations of FIMO and correlation parameter thresholds (data not shown). The first 
and second maps were produced using cut-off values that maximized the Fisher’s exact test for non-
random association between negatively correlated RBP expression and PSIs and the presence of RBP 
binding motif for regions s2_I and e2_E, respectively. 
Similar to what had been observed with PCBP3, RNA splicing maps derived from TCGA data looked 
very different from the ones obtained from the GTEx data. This was somehow unexpected because 
of the highly concordant correlation results referred above between the two datasets, which 
automatically implied that a similar pool of alternative splicing events with the same KHDRBS2 
binding motifs in their mRNA regulatory regions would be accounted for during map generation. 
However, the amount of alternative splicing events used for the generation of the maps was much 
lower for TCGA than for GTEx: 4369 and 14769, respectively. This tremendous difference derives 
mostly from the fact that the TCGA genome annotation contemplated 17533 SE events, while the 
annotation used for analysis of GTEx data, the GENCODE annotation, included 35465 SE events. This 
difference is indeed illustrated by the difference in the maximum enrichment significance achieved 
with both datasets (p ≈ 10-2 vs p ≈ 10-6). Such weakness could be solved through the analysis of raw 
RNA-seq data for TCGA glioma cohort using the GENCODE genome annotation.  
Finally, RNA splicing maps were also produced for IGF2BP2, a ubiquitous protein that appeared 
upregulated in LGm groups 1,4,5 and 6 in relation to LGm2 and LGm3 (Figure 3.30). In the case of 
this RBP, the two regulatory regions that showed better non-random association between the 
effects of RBP expression and the presence of RBP binding motif on splicing ratios were the same for 
the two data sets: the intronic region upstream from the regulated exon (s2_I) and the beginning of 
the second constitutive exon (s3_E), although statistical significance was higher for s2_I region in the 
GTEx dataset and for s3_E region in the TCGA dataset. Interestingly, for the GTEx data set no peaks 
for the s3_E region appeared in either map. Instead, apart from the silencer peak in s2_I region at 
around 90 bp from the start of the alternative exon, there was an enhancing peak at 50 bp of the 
same intronic region and also another enhancing peak spanning a large portion of region e2_I. These 
two peaks representing an enhancer activity of IGF2BP2 had been detected through the application 
of Fisher’s exact test for positively correlated events on the 150 bp-spanning regions, though their 
corresponding p-values were not among the two highest. In the second TCGA RNA splicing plots, it is 
possible to observe a silencing and an activating peak in the intronic region that precedes the 
alternative exon, as much as in the GTEx maps, though at low levels of significance. However, in this 
map there are other peaks that could indicate an IGF2BP2 regulatory role, all of them having a low y-
axis coordinate, that corresponds to a p-value above 0.01. The top map obtained from the TCGA 
cohort shows an enhancing peak of higher significance at exonic region s3_E, which was expected to 
appear for the GTEx cohort as well. 
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Figure 3.30 – KHDRBS2 RNA-binding maps for the general exon-skipping (SE) alternative splicing event. (A) Two RNA-
binding maps produced using the GTEx multi-tissue dataset. (B) Two RNA-binding maps produced using the glioma TCGA 
dataset. RNA-binding maps shown were generated using correlation FDR threshold and FIMO p-value as shown on the 
bottom and the right side of the heat maps, respectively. Distance in base pairs (bp) relative to the closest splice site is 
shown. Different names for the eight intronic (150 nucleotides long) and exonic (50 nucleotides long) regulatory regions 
defined are indicated in grey. Constitutive exons are shown in black and alternative exon is shown in white. Corr-type – 
Correlation type: blue for enhancement and red for silencing of exon inclusion. 
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Figure 3.31 – IGF2BP2 RNA-binding maps for the general skipped exon (SE) alternative splicing event. (A) Two RNA-binding 
maps produced using the GTEx multi-tissue dataset. (B) Two RNA-binding maps produced using the glioma TCGA dataset. 
RNA-binding maps shown were generated using correlation FDR threshold and FIMO p-value as shown on the bottom and 
the right side of the heat maps, respectively. Distance in base pairs (bp) relative to the closest splice site is shown. Different 
names for the eight intronic (150 nucleotides long) and exonic (50 nucleotides long) regulatory regions defined are indicated 
in grey. Constitutive exons are shown in black and alternative exon is shown in white. Corr-type – Correlation type: blue for 
enhancement and red for silencing of exon inclusion. 
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In this section, the analysis of RNA splicing maps for five splicing factors showed the value of this 
novel approach of integrating alternative splicing profiles with RBP binding predictions in order to 
outline possible mechanisms of alternative splicing regulation. It also showed how the application of 
this procedure to two datasets can assist in forming more robust hypotheses that can then be tested 
experimentally. However, the use of much fewer alternative splicing events in the TCGA data may 
actually be the main cause for the incoherencies found in the RNA splicing map analyses.  
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 DISCUSSION 
To date there are two publications dedicated to the study of malignant glioma in a transversal way 
across grades 2 to 4 (Ceccarelli et al., 2016; Z.-L. Z. Wang et al., 2015), both dealing with GBM and 
LGG TCGA glioma cohorts. The study from Wang and collaborators allowed to identify a group of 
1091 genes which at both mRNA and DNA-methylation level distinguished glioma samples in 
between grades and thus across levels of malignancy. Among the 977 genes showing upregulation in 
higher grades, the main enriched functional category was cell cycle. The work from Ceccarelli and 
collaborators was also a multi-platform integrative study in which the authors were able to create a 
glioma classifier based on 932 DNA-methylation probes, which has the resolution to distinguish 
more than the three previously identified glioma epigenetic classes: IDH-mutant non-codel, IDH-
mutant codel and IDH-wiltype glioma classes. Indeed, IDH-mutant non-codel glioma was further 
divided in two with differing levels of DNA-methylation levels, with LGm1 subtype, the one with 
lower DNA-methylation, constituting a poorer prognosis group shown to frequently correspond to 
advanced stages of the disease in relation to the closely-related LGm2 subtype. Then, within IDH-
wild type glioma, three subtypes could also be distinguished, with LGm6 constituting a 
heterogeneous, overall better prognosis class, sharing epigenetic and genetic characteristics with 
the often benign tumour pilocytic astrocytoma. The ability of this molecular classifier to diagnose 
novel groups with differential prognosis rendered it a quite powerful means of, together with the 
established glioma prognosis indicators grade and age, performing an evaluation of a patient’s 
predicted disease outcome as well as investigating therapeutic strategies favourable to each 
particular molecular subtype, both dealing with GBM and LGG TCGA cohorts(Ceccarelli et al., 2016; 
Z.-L. Z. Wang et al., 2015). 
This thesis focused in the analysis of the RNA-seq GBM and LGG data sets from the TCGA portal in 
order to establish the contribution of alternative splicing regulation to the definition of subtypes of 
glioma grades 2 to 4. 
Initial exploratory data analysis of the 659 glioma cases cohort allowed to determine that the 
majority of alternative splicing events had their exon-inclusion ratios correlated with levels of 
transcription of their cognate gene. Evaluation of the association between gene expression and 
alternative splicing was carried out with the main purpose of identifying which events of splicing 
might be influenced by rates of transcription. This information could then be taken into account 
when studying mechanisms of alternative splicing regulation in trans, as the identified alternative 
splicing events would be known to have splicing ratios determined by an interaction between levels 
of gene expression and the actual relative abundances of active splicing factors. The set of 
alternative splicing events found to be more strongly associated with gene expression had a 
distribution of PSI variances higher than the set that displayed a weaker association. This difference 
could stem from the fact that some low variance events actually associated with gene expression 
could have failed to be detected by correlation analysis, which would have resulted in a reduced but 
biased number of low variance events among the set of events with high association with gene 
expression. This was interpreted as an indication that the group of events less associated with gene 
expression could be less rich in interesting alternative splicing events descriptive about differences 
between glioma grades and DNA methylation subtypes. However, while performing the analysis of 
differential splicing across LGm subtypes, it became clear that the ability for alternative splicing 
events to help distinguish glioma subtypes was frequently not dictated by the overall amount of 
variation of their PSIs. 
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Analysis of the main principal components of variance of alternative splicing and gene expression 
data allowed to make some interesting findings. Firstly, one main principal component common to 
gene expression and alternative splicing events, all combined and separated by type, is clearly linked 
to malignancy. Indeed, samples of grades 2 and 4 glioma cases separated well away from each other, 
while grade 3 samples mapped along that axis, which presumably reflected a gradient of tumour 
aggressiveness, later corroborated by survival analyses. In contrast, LGm groups 4 and 5 could not be 
resolved either by gene expression or by alternative splicing main principal components of variance. 
Samples from LGm groups 1 and 6 showed no trend in the way they spread along the “malignancy” 
principal components. This behaviour is likely linked with the heterogeneity of these subtypes and 
was also visible in other analyses, for example while inspecting individual alternative splicing event 
PSI distributions. Indeed, LGm1 samples dispersion along the malignancy PC could be thought of as 
corresponding to various stages of disease progression from a previous, more homogeneous, LGm2 
stage. In turn, LGm6 samples, which in the cohort in study corresponded at almost equal frequencies 
to grades 2, 3 and 4, could easily be understood to occupy the whole range of positions along gene 
expression and alternative splicing malignancy-associated principal components.  
Glioma classifiers built based on gene expression data (i.e. transcriptome subtype and RNA 
expression cluster) had samples, as expected, sharply separated across the two first principal 
component of gene expression, while alternative splicing data provided a similar separation along 
combinations of principal component 2 with other main principal components. However, it was 
apparent from this exploratory analysis methodology plots how the high malignancy samples formed 
more homogeneous groups, whose diversity is not even addressed in the pan-glioma RNA-
expression cluster classification.    
PCA analysis of data different alternative splicing event types brought as main interesting finding 
that alternative 3’ splice site events behaved quite differently in glioblastoma as compared to low-
grade glioma. This observation actually constituted the only instance of separation of sample 
categories into discrete clusters coming from alternative splicing data and should be further 
investigated. Up to this moment, the only preliminary analysis done to try to understand the nature 
of this particular A3 alternative splicing behaviour was to check if A3 PSIs were more sensitive to 
levels of cognate gene expression, through comparative correlation analyses. This possibility was not 
supported. Also, the hypothesis that only a subset of A3 alternative splicing events with particular 
features, such as consistent splice site strength differences between the two alternative splice sites 
under selection, was driving the separation between GBM and LGG was briefly explored. Specifically, 
the distribution of loadings along PC2 of A3 alternative splicing events was inspected and, from the 
2093 A3 alternative splicing events analysed, about 1248 were found to make a larger contribution 
to PC2. An interesting class of concurrent 3’ splice sites is the one of tandem alternative splice sites 
(TASS), also termed NAGNAG, which constitute a particular group of A3 alternative splicing in which 
the mature mRNA isoforms differ by three NAG nucleotides. Although NAGNAG motifs are frequent 
in the human genome, only a subset of these (around 215) are subject to alternative splicing 
(Akerman, David-Eden, Pinter, & Mandel-Gutfreund, 2009). Because TASS alternative splicing 
appears to be heavily regulated and, very interestingly, switches in TASS splice site usage have been 
observed in cells that grow under confluence in cell culture (Szafranski et al., 2014), a condition that 
could be similar to the one happening in rapid growth tumour masses, the possibility of enrichment 
of TASS among the A3 splice sites contributing with higher variance to A3 PC2 should be explored. 
While alternative splicing appeared to have similar discriminatory power towards known glioma 
clinical and molecular classes, it was also shown here to underlie different levels of biological 
information. Indeed, alternative splicing was found to keep very similar principal components of 
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variance when analysed without the pool of events significantly dependent on gene expression 
(Figure 3.9 of Results section). When functional analysis was performed on the gene expression and 
alternative splicing malignancy dimensions through GSEA, the enriched functional pathways found 
for the former were not found for the latter, except for the KEGG dilated cardiomyopathy pathway. 
Still, enrichment for this functional category was driven by different genes in the two analyses.  
The study followed having as a main focus the elucidation of the differences in gene expression and 
alternative splicing regulation between LGm subtypes, which being molecularly more homogeneous 
than tumour grades and constituting a classification system with very valuable information in terms 
of prognosis, were thought of as promising entities to analyse. 
A group of 5970 genes were differentially expressed between LGm groups, from which 183 
corresponded to known tumour drivers and various to be associated with glioma, like ErbB tyrosine 
kinase receptor genes, cell proliferation related genes such as CDKN2C or MDM2, and the DNA CpG 
demethylator enzyme encoding TET1. Importantly, 41 splicing factors also appeared differentially 
expressed between LGm subtypes, with LGm groups 4 and 5, on the one hand, and LGm groups 2 
and 3, on the other, usually presenting closer values of expression, while LGm groups 1 and 6 
expressed these genes sometimes more similarly to the referred IDH-wild type subtypes and other 
times more similarly to IDH-mutant subtypes LGm2 and LGm3. PTBP1, whose overexpression in 
glioblastoma is known to enhance tumour survival and invasiveness, did not surpass the fold-change 
threshold used for selection of differential gene expression, but was considerably upregulated in 
LGm groups 4 and 5. Because some of its known alternative splicing event targets, such as the 
skipping exon 3 of RTN4 gene, also appeared differentially spliced between LGm groups, it is possible 
that even small changes in PTBP1 transcriptional output are enough to switch isoform ratios of its 
targets in the cell. It remains to be ascertained though if this transcription factor is significantly 
upregulated in all glioma subtypes relatively to healthy adult brain tissues. Finally, there were 13 
splicing factors among the differentially expressed genes whose RNA binding motif was known and 
that thus constituted good putative regulators of key glioma-specific alternative splicing events. 
Analysis of differential splicing across DNA-methylation cluster subtypes was carried out using the 
non-parametric ANOVA equivalent Kruskal-Wallis statistical test. However, considering the usual 
levels of significance applied to statistical testing (e.g. FDR = 0.01 or FDR = 0.001), many differentially 
regulated alternative splicing events presented PSI distributions for the different LGm subtypes that 
overlapped in great extent. This test alone was therefore not powerful enough to efficiently identify 
a set of alternative splicing events reflecting clear modes of regulation particular of the different 
LGm subtypes, as desired. For this reason, selection of differentially regulated alternative splicing 
events was carried out using a significance level of 1 x 10-9 and establishing a minimum difference of 
median PSI values between at least two LGm groups of 0.1. A total of 1762 alternative splicing 
events were found to be subjected to differential splicing according to these criteria. Among the 
genes differentially spliced there were 89 known cancer drivers, 64 of which were not differentially 
expressed between glioma subtypes. This observation was quite interesting because it raised the 
possibility that some of these alternative splicing events might be undergoing isoform ratio changes 
due to somatic mutations affecting their splice sites and/or splicing regulatory elements. Although 
few DNA lesions present in tumours attain such high incidences that they become common traits 
transversal to most samples from a given tumour subtype, this hypothesis of the existence of 
recurrent (frequent) splicing-affecting mutations should be further analysed.  
There were 46 splicing factor genes being subjected to differential splicing, none of them 
differentially expressed. Many of the alternative splicing events happening on these 46 genes had 
unknown consequences in terms of functional impact on the resulting protein. It could be interesting 
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to test experimentally the effect of these different splicing isoforms in cell tumourigenicity. In 
addition, it should be investigated which of the differentially regulated alternative splicing events 
involved introduction of premature stop codons and thereby putative induction of nonsense-
mediated decay, so as to evaluate the extent at which splicing alterations regulate expression of 
certain genes in glioma cells.   
Functional enrichment analysis performed on information from gene expression and alternative 
splicing differential regulation in LGm subtypes revealed once again differing biological functions 
being affected by each transcriptional process. Whereas genes with differences in expression across 
DNA-methylation clusters were related with functions like immune response, cell proliferation, cell 
survival or cell adhesion, genes having their alternative splicing affected were mostly involved in 
RNA-processing, protein synthesis and also apoptosis.       
Although alternative splicing events displaying differential regulation across LGm groups did not 
seem to be able to distinguish between LGm4 and LGm5 groups, they could potentially be used for 
identification of LGm groups 2,3, and 4/5. This could be particularly useful for the diagnosis of glioma 
samples for which DNA-methylation data would not be available. LGm1 and LGm6 subtypes, shown 
to add important prognostic value to the DNA-methylation pan-glioma classifier published by 
Ceccare lli and collaborators, could not be accurately identified merely based on alternative splicing 
nor gene expression data. Still, it is likely that the identified glioma subtype alternative splicing 
markers combined with epigenetic data could help in further stratifying patients in terms of 
prognosis. This approach of combining epigenetic and transcriptomic data was actually already used 
in the lastly cited article. Specifically, grade classification assessed through histological analysis was 
replaced by expression of certain genes (“EReg” genes) in order to separate LGm6-LGG patients from 
LGm6-GBM patients.  
A study of the value of alternative splicing and gene expression in glioma prognosis was then 
performed. Initially, a confirmation that the previously identified principal components of variance 
of alternative splicing and gene expression contained valuable information associated with 
malignancy was made. Indeed, Cox proportional-hazards models applied to explain patients’ overall 
survival with WHO grade categories, on the one hand, and with PC loadings on the other, showed 
these dimensions to be advantageous over grade in glioma prognosis prediction, as judged from the 
Harrell’s concordance index metric for evaluation of the survival regression models.  
Then, the prognostic value of individual genes and alternative splicing events was evaluated, alone 
or after adjustment for known clinical and molecular prognostic factors. Importantly, individual 
alternative splicing and expressed gene markers were shown to add only negligible prognosis 
information to a model that already took into account LGm subtype, tumour grade and age of the 
patient. In fact, only two alternative splicing events and one expressed gene made a significant 
contribution to the previously referred multivariate Cox regression model. The two alternative 
splicing events in question had very narrow PSI distributions, being difficult to work with if ever used 
as prognostic markers and were also likely not interesting per se in terms of representing isoform 
switches with biological impact. It should be added though that it might be possible to derive a 
selected group of alternative splicing markers and/or genes able to add prognostic value to the 
glioma Cox regression model for patient’s overall survival composed of LGm subtype, grade and age. 
The selection of markers to build such meta feature could be made from a list of prognostic markers 
identified in Cox regression models adjusted for LGm group and age, but not for grade. Indeed, both 
gene expression and alternative splicing had been shown to be superior in relation to grade in what 
concerns capturing malignancy.     
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It was then considered relevant to identify expressed genes, namely splicing factor genes, and 
alternative splicing events associated with LGm groups. This analysis involved the identification of 
markers whose prognostic values were independent of tumour grade and patient’s age, since it was 
known that any prognostic information added to these two factors would likely be included in the 
LGm classifier. There were 3727 expressed genes and 237 alternative splicing events that showed to 
add prognostic value to the above-mentioned model settings. Further application of Cox regression 
to the LGG, but not to the GBM cohort separately, proved very useful, having helped to identify 493 
additional glioma prognostic alternative splicing events. Unfortunately, the GBM cohort returned no 
significant prognostic markers able to discriminate subsets of glioblastoma patients with differential 
expected outcome. This is likely due to the reduced size of GBM patients used in this study, which 
could apparently not represent enough variation in dependent and/or independent variables in the 
models created in order to reach statistical significance during prognostic marker evaluation.      
Finally, having in mind the aim to identify a final list of alternative splicing regulators and events 
clearly associated with the LGm groups and having prognostic value, the markers obtained from the 
survival analysis that also corresponded to differentially regulated genes and alternative splicing 
events were extracted. This selection returned 20 splicing factors, from which six with known RNA-
binding motif, whose potential as regulators of differential alternative splicing across LGm groups 
was evaluated at a later stage. In turn, 337 alternative splicing events associated with DNA-
methylation subtype classification were identified. From these, there were 50 that were 
independent of gene expression and, consistently, were also not related with genes having 
themselves prognostic value in glioma.      
In the final results section of this manuscript, potential mechanisms of alternative splicing regulation 
in trans relevant in particular LGm glioma subtypes were looked for. Different publications dedicated 
to the study of alternative splicing regulation in cancer have brought evidence to the fact that 
alterations in exon-inclusion ratios in this disease are only rarely strongly associated with mutations 
in cis elements (Sebestyén, Zawisza, et al., 2015) or with mutations in RNA-binding protein genes 
(Sebestyén, Singh, et al., 2015). These two observations make it particularly pertinent to try to 
assess mechanisms of alternative splicing regulation through identification of strong relations 
between active RNA-binding splicing factors and exon-inclusion ratios of their potential targets. An 
attempt to find these relations was made that consisted of looking for non-random association 
between two variables:  correlation of splicing factor gene expression with alternative splicing event 
quantifications and occurrence of splicing factor binding motifs in regulatory regions of alternative 
splicing events. This analysis was made individually for eight distinct regulatory regions of general 
exon-skipping events, shown in the literature to create independent contexts for context-specific 
alternative splicing regulation. 
The likeliness for each of the six RNA-binding splicing factors RBM47, RBMS1, IGF2BP2, IGFBP3, 
KHDRBS2 and PCBP3 to constitute splicing regulators of a considerable portion of exon-skipping 
events was assessed by looking at concordance of RBP expression/PSI correlations between the 
GTEx and the glioma TCGA datasets. KHDRBS2 encoding gene seemed to show the best concordance 
between both datasets. Subsequently, information about the actual presence of binding motifs for 
these RBPs in SE events regulatory regions was collected, promisingly showing an enrichment in the 
number of alternative splicing events that contained RBP motifs (cis elements) together with 
significant correlation with RBP expression among those that were differentially regulated across 
LGm subtypes.  
RNA splicing maps were then derived, first for PTBP1, in order to validate the algorithm used, and 
then to the other RBPs with strong association with LGm subtypes. RNA splicing maps for PTBP1 very 
76 
 
nicely reproduced what had been found in the literature in terms of the mode of action of this 
splicing regulator, both using GTEx multi tissue and TCGA glioma datasets. However, for the other 
RBPs, discrepancies were found between the maps produced using both datasets. Still, the KHDRBS2 
GTEx-derived RNA splicing maps seemed quite reliable, both in terms of the level of significance of 
the highest peaks of discovered regulatory regions and also the stability of their relative position 
under different parameter settings (data not shown).  
In the future, some improvements to the RNA splicing map generating algorithm used here may be 
made in order to be able to take stronger conclusions on RBP-specific alternative splicing regulation 
mechanisms and, in particular, about the possibility to detect common modes of regulation in 
tumourigenic vs healthy tissue. As such, the main proposed change on the algorithm itself would be 
to start accounting for the total number of RBP motifs in each region searched. In our analyses, 
enrichment tests were run on the binary information of each alternative splicing event being bound 
or not, meaning a maximum count of one motif per event. Then, TCGA data should be analysed 
using a more comprehensive transcriptomic annotation, so that more alternative splicing events can 
be profiled and the power of the statistical tests thereby increased. 
Some concluding remarks may be noted. The work presented here allowed the elucidation of the 
relative contribution of alternative splicing for glioma subtype assessment, namely relatively to gene 
expression and DNA-methylation data levels. Characterization of alternative splicing profiles in 
different glioma grades and LGm subtypes brought some interesting new findings that can be further 
explored to help in the identification of mechanisms of splicing regulation affected in particular 
glioma groups and also in the improvement of patient clinical management, following to a better 
stratification according to prognosis. As main drawbacks associated with this work, limiting the 
discovery potential but not compromising the quality of the results presented, were the sub-optimal 
transcriptome annotation underlying the glioma data and impossibility of profiling tumour-specific 
aberrant splicing due precisely to the use of data processed based on a reference transcriptome.    
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 SUPPLEMENTS 
Table S 1 – Class designations, histological codes and tumour grading of gliomas by the 2016 WHO Classification of CNS 
tumours (Louis et al., 2016). 
Designation Histology ICH id* WHO grade 
Diffuse astrocytic and oligodendroglial tumours   
Diffuse astrocytoma, IDH-mutanta 9400/3 II 
Diffuse astrocytoma, IDH-wildtypea 9400/3 II 
Anaplastic astrocytoma, IDH-mutanta 9401/3 III 
Anaplastic astrocytoma, IDH-wildtypea 9401/3 III 
Glioblastoma, IDH-wildtypeb 9440/3 IV 
Glioblastoma, IDH-mutantb 9445/3 IV 
Diffuse midline glioma, H3 K27M-mutant 9385/3 IV 
Oligodendroglioma, IDH-mutant and 1p/19q-
codeleteda 
9450/3 II 
Anaplastic oligodendroglioma, IDH-mutant and 
1p/19q-codeleteda 
9451/3 III 
Other astrocytic tumours   
Pilocytic astrocytoma 9421/3 I 
Subependymal giant cell astrocytoma 9384/1 I 
Pleomorphic xanthoastrocytoma 9424/3 II 
Anaplastic pleomorphic xanthoastrocytoma 9424/3 III 
Other gliomas   
Chordoid glioma of the third ventricle 9444/1 II 
Angiocentric glioma 9431/1 I 
* Morphology code coming from the International Classification of Diseases for Oncology 
a Included in LGG-TCGA cohort 
b Included in GBM-TCGA cohort 
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Figure S 1 – Scatter plot of primary-recurrent glioma paired samples across PSI matrix principal components 1 and 2. 
Samples from the same patient are identified by one “Case” colour and the plotted symbol illustrates the sample type. 
Underlying PCA was performed on the whole glioma cohort and only paired samples plotted for a clearer visualization of 
their relative positions. 
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Figure S 2 – Principal Component Analysis scatter plots of alternative splicing data, coloured for sample source centre and 
sample library size. Numbers in the library size labels represent total numbers of mapped reads, with samples separated by 
quartiles of library sizes in the glioma cohort.  Numbers in the library size labels represent total numbers of mapped reads 
and correspond to size boundaries that correspond to the three quartiles of library sizes in the glioma cohort.  
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Figure S 3 – Distributions of different parameters related with somatic DNA alterations and tumour purity in two groups of 
samples behaving differently along alternative splicing principal component 1.  
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Figure S 4 – Concordance indexes for different Cox regression models applied to the glioma cohort, using recognized clinical 
and molecular variables.  
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Table S 2 – Summary statistics of Cox regression models including significant alternative splicing events, after adjustment 
for gene expression, DNA-methylation cluster, WHO grade and age. FDR cut-off value: 0.05.  
Event Gene GE.HR PSI.HR Concordance PSI.FDR logrank.FDR 
COPS4;SE:chr4:83989675-83994358:83994506-83996449:+ COPS4 0,78 2,30E-09 0,865 0,02 0,00 
CTSB;SE:chr8:11710988-11715366:11715449-11725509:- CTSB 1,46 7,29E+32 0,875 0,04 0,00 
DENND5B;SE:chr12:31648853-31652539:31652605-31743639:- DENND5B 1,08 4,32E+06 0,865 0,02 0,00 
FGF1;SE:chr5:141993726-142077186:142077280-142077477:- FGF1 0,95 8,99E-02 0,868 0,02 0,00 
LPXN;SE:chr11:58322413-58331627:58331674-58338028:- LPXN 1,04 1,03E+02 0,865 0,03 0,00 
LRIG1;SE:chr3:66449465-66452032:66452104-66455621:- LRIG1 0,93 2,94E+25 0,864 0,03 0,00 
MIB2;SE:chr1:1560808-1560925:1561033-1562029:+ MIB2 0,72 1,20E-02 0,868 0,03 0,00 
MRO;SE:chr18:48326513-48327718:48327874-48331523:- MRO 0,92 7,46E+00 0,865 0,04 0,00 
NAGPA;SE:chr16:5078186-5078297:5078399-5078880:- NAGPA 1,26 1,90E-05 0,864 0,04 0,00 
NAP1L4;SE:chr11:3000467-3010358:3010501-3013483:- NAP1L4 0,81 3,93E+10 0,865 0,02 0,00 
NLGN4X;SE:chrX:6069812-6105523:6105830-6146581:- NLGN4X 1,03 1,99E+30 0,865 0,00 0,00 
PDE8A;SE:chr15:85632647-85634274:85634412-85641178:+ PDE8A 0,98 4,94E-02 0,857 0,02 0,00 
PDGFRA;SE:chr4:55124984-55127261:55127579-55129833:+ PDGFRA 1,04 5,11E-10 0,871 0,00 0,00 
POLR2J4;SE:chr7:44053278-44054204:44054382-44056032:- POLR2J4 1,02 3,84E+01 0,866 0,05 0,00 
PSMB5;SE:chr14:23495584-23496953:23497038-23502576:- PSMB5 1,17 8,17E+17 0,866 0,04 0,00 
RBM42;SE:chr19:36125275-36128059:36128254-36128343:+ RBM42 0,95 5,75E-186 0,862 0,04 0,00 
RMND5B;SE:chr5:177558377-177562173:177562313-
177565108:+ 
RMND5B 0,57 7,87E-07 0,870 0,03 0,04 
SLIT1;SE:chr10:98791434-98794227:98794299-98797454:- SLIT1 0,94 1,03E-04 0,865 0,04 0,00 
SNRPN;SE:chr15:25207356-25213078:25213229-25219457:+ SNRPN 0,67 3,72E-48 0,868 0,03 0,00 
STYXL1;SE:chr7:75625917-75630207:75630320-75633075:- STYXL1 1,08 1,74E-02 0,864 0,05 0,00 
ZNF33A;SE:chr10:38299711-38301225:38301278-38305798:+ ZNF33A 0,64 1,45E+01 0,867 0,04 0,00 
ASTN2;RI:chr9:119187506:119187905-119188188:119188367:- ASTN2 1,00 1,33E-04 0,865 0,04 0,00 
HRAS;RI:chr11:532242:532522-532630:532755:- HRAS 0,88 1,63E+03 0,865 0,03 0,01 
CWC25;A5:chr17:36977326-36981418:36977326-36981522:- CWC25 0,75 6,86E-04 0,866 0,02 0,00 
PCBP4;A5:chr3:51993308-51993378:51993308-51993382:- PCBP4 0,94 2,32E+23 0,865 0,04 0,00 
PNPLA8;A5:chr7:108154737-108154875:108154737-
108154879:- 
PNPLA8 0,79 4,91E+13 0,863 0,02 0,00 
SAE1;A5:chr19:47634369-47646750:47634285-47646750:+ SAE1 0,84 8,76E+01 0,866 0,03 0,00 
TMX1;A5:chr14:51712172-51713809:51712076-51713809:+ TMX1 1,04 1,60E+22 0,867 0,03 0,00 
TOMM5;A5:chr9:37588929-37592306:37588929-37592408:- TOMM5 1,06 1,06E+17 0,869 0,05 0,00 
TTC8;A5:chr14:89307272-89307380:89307267-89307380:+ TTC8 0,75 3,62E+60 0,871 0,03 0,00 
CDV3;A3:chr3:133305566-133306002:133305566-133306005:+ CDV3 1,05 6,66E+01 0,867 0,02 0,00 
IMMT;A3:chr2:86398459-86400772:86398435-86400772:- IMMT 1,34 2,51E+40 0,859 0,02 0,00 
RANBP1;A3:chr22:20113891-20114474:20113891-20114477:+ RANBP1 0,85 4,25E-03 0,867 0,03 0,00 
RBM8A;A3:chr1:145508075-145508206:145508075-
145508209:+ 
RBM8A 0,98 2,16E-03 0,868 0,03 0,00 
ELOVL1;AF:chr1:43831294-43833156:43833361:43831294-
43833585:43833699:- 
ELOVL1 1,09 2,60E+09 0,869 0,02 0,00 
HNRNPUL1;AF:chr19:41770639:41770703-
41774127:41771026:41771248-41774127:+ 
HNRNPUL1 0,88 7,09E-02 0,867 0,04 0,00 
MED15;AF:chr22:20861885:20862033-
20891403:20862338:20862731-20891403:+ 
MED15 0,69 3,22E-05 0,866 0,05 0,00 
NDRG2;AF:chr14:21492255-21492984:21493185:21492255-
21493835:21493935:- 
NDRG2 1,01 3,86E-05 0,869 0,03 0,00 
TSC22D3;AF:chrX:106959180-
106959544:106959711:106959180-107018329:107019017:- 
TSC22D3 0,90 3,89E-02 0,865 0,04 0,00 
TUBB3;AF:chr16:89988416:89988653-
89998978:89989744:89989866-89998978:+ 
TUBB3 1,27 1,50E+14 0,870 0,03 0,00 
EIF4E2;AL:chr2:233431924-233433654:233433919:233431924-
233445613:233448349:+ 
EIF4E2 0,66 1,03E+01 0,864 0,04 0,00 
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Figure S 5 – Concordance between glioma TCGA and GTEx established splicing factor to alternative splicing events PSIs 
correlations.  Scatter plots comparing the two data sets for -log10(FDR) values times the sign of the Spearman correlation 
rho between RBP expression and PSIs, for each RBP splicing factor. 
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Figure S 6 – PTBP1 RNA-binding maps for the general exon-skipping (SE) alternative splicing event.  . (A) Two RNA-binding 
maps produced using the GTEx multi-tissue dataset. (B) Two RNA-binding maps produced using the glioma TCGA dataset. 
RNA-binding maps shown were generated using correlation FDR threshold and FIMO p-value as shown on the bottom and 
the right side of the heat maps, respectively. Distance in base pairs (bp) relative to the closest splice site is shown. Different 
names for the eight intronic (150 nucleotides long) and exonic (50 nucleotides long) regulatory regions defined are indicated 
in grey. Constitutive exons are shown in black and alternative exon is shown in white. Corr-type – Correlation type: blue for 
enhancement and red for silencing of exon inclusion.  
